Poster Presentations Session II

RESEARCH ON METHODS & CONCEPTUAL PAPERS Clinical Outcomes Studies
PMC1	SEARCH STRATEGIES AND RESULTS OF SYSTEMATIC REVIEWS
	Proudfoot C, Plested M, Buckley F
	Heron Evidence Development Ltd, Letchworth Garden City, Hertfordshire, UK

PMC2	WHEN ARE INDIRECT AND MIXED TREATMENT COMPARISONS BIASED? A GRAPHICAL EXPLANATION WITH DAGS
	Jansen JP
	Mapi Values, Boston, MA, USA
RESEARCH ON METHODS & CONCEPTUAL PAPERS Cost Studies
PMC3	METHODS FOR ESTIMATING CONFIDENCE INTERVALS OF PER MEMBER PER MONTH (PMPM) UTILIZATION RATES
	Saverno K1, Goodman M2
	1University of Arizona College of Pharmacy, Tucson, AZ, USA, 2Xcenda, Woodbury, MN, USA

PMC4	THE ADOPTION AND DIFFUSION OF COST-EFFECTIVENESS ACCEPTABILITY CURVES IN PUBLISHED ECONOMIC EVALUATIONS
	Greenberg D1, Cohen JT2, Neumann PJ2
	1Ben-Gurion University of the Negev, Beer-Sheva, Israel, 2Tufts-New England Medical Center, Boston, MA, USA

PMC5	AN ANATOMY OF PHARMACEUTICAL COST-UTILITY ANALYSES, 1976-2005
	Fang C, Cohen JT, Neumann PJ
	Tufts-New England Medical Center, Boston, MA, USA

PMC6	THE $50,000/QALY THRESHOLD RECONSIDERED: A RETROSPECTIVE ON KLARMAN'S ORIGINAL PAPER WITH AN EYE TO THE FUTURE
	Nauenberg E
	University of Toronto, Toronto, ON, Canada

PMC7	TOTAL DIRECT MEDICAL EXPENDITURE OF CHRONIC DISEASES UNDER DIFFERENT ECONOMETRIC MODELS
	Kawatkar AA, Nichol MB
	University of Southern California, Los Angeles, CA, USA

PMC8	A CONCEPTUAL FRAMEWORK TO ANALYZE A DISEASE'S WORKPLACE IMPACT ON AN EMPLOYER
	Sun P
	Kailo Research Group, Indianapolis, IN, USA

PMC9	30 YEARS OF COST-EFFECTIVENESS ANALYSES: A BIBLIOMETRIC REVIEW OF ARTICLES PUBLISHED IN THE ECONOMIC AND MEDICAL LITERATURE: 1976-2005
	Greenberg D1, Rosen AB2, Palmer JA3, Wacht O1, Neumann PJ3
	1Ben-Gurion University of the Negev, Beer-Sheva, Israel, 2University of Michigan Health Systems, Ann Arbor, MI, USA, 3Tufts-New England Medical Center, Boston, MA, USA

PMC10	THE DEVELOPMENT OF COST-EFFECTIVENESS INDICES WITH EQUITY IMPLICATIONS FOR THE ECONOMIC EVALUATION OF HEALTH CARE
	Hu FC1, Wang JD2
	1National Taiwan University Hospital, Taipei, Taiwan, 2National Taiwan University, Taipei, Taiwan

PMC11	ACCOUNTING FOR THE PLACEBO RESPONSE IN COST-EFFECTIVENESS ANALYSIS
	McDonald HP1, Rebeira M1, Wright S2, Jaszewski B1
	1Bayer Inc, Toronto, ON, Canada, 2GW Pharma Ltd, Salisbury, UK

PMC12	MEASURING ECONOMIC AND CLINICAL OUTCOMES ASSOCIATED WITH TELE-ICU MONITORING
	Franzini L1, Sail K1, Wueste L2, Thomas E2
	1University of Texas School of Public Health, Houston, TX, USA, 2University of Texas Medical School at Houston, Houston, TX, USA

RESEARCH ON METHODS & CONCEPTUAL PAPERS Database Studies & Management
PMC13	USE OF POTENTIALLY INAPPROPRIATE PSYCHOACTIVE MEDICATIONS AND FALLS IN U.S. NURSING HOME RESIDENTS
	Agashivala N, Wu W
	St. John's University, NY, NY, USA

PMC14	EXPLORING CANDIDATE DIFFERENCES BETWEEN DRUG COHORTS PRIOR TO EXPOSURE: A SYSTEMATIC APPROACH USING MULTIPLE OBSERVATIONAL DATABASES
	Ryan PB, Powell GE
	GlaxoSmithKline, Research Triangle Park, NC, USA

PMC15	DETERMINING THE MECHANISM OF MISSING DATA IN INCOMPLETE DATASETS
	Whillans F1, Tarride JE2, Blackhouse G2, Hopkins R2, Goeree RA2
	1Dymaxium Inc, Toronto, ON, Canada, 2McMaster University, Hamilton, ON, Canada

PMC16	CREATING NATIONAL WEIGHTS FOR A LARGE-SCALE, PATIENT LONGITUDINAL DATABASE
	Baser O1, Polingo L2, Schaeffer J3, Maguire J4, Mummidi V4
	1STATinMED Research and University of Michigan, Ann Arbor, MI, USA, 2i3, Minneapolis, MN, USA, 3i3, Milford, MI, USA, 4i3, Basking Ridge, NJ, USA

PMC17	A METHOD FOR CONVERTING NATIONAL DRUG CODES (NDCS) TO GENERIC AND THERAPEUTIC CATEGORY CODES FOR USE IN LARGE DATABASE STUDIES OF PRESCRIPTION DRUG CLAIMS
	Dickson M
	University of South Carolina, College of Pharmacy, Columbia, SC, USA

PMC18	COMPARISONS OF DATA MINING ALGORITHMS FOR ADVERSE DRUG REACTIONS: AN EMPIRICAL STUDY BASED ON THE ADVERSE EVENT REPORTING SYSTEM OF THE FOOD AND DRUG ADMINISTRATION
	Chen Y1, Guo JJ2, Patel NC3, Steinbuch M4, Lin XD2, Buncher C1
	1University of Cincinnati Medical Center, Cincinnati, OH, USA, 2University of Cincinnati, Cincinnati, OH, USA, 3University of Georgia, Augusta, GA, USA, 4P&G Pharmaceuticals, Inc, Mason, OH, USA

PMC19	ESTIMATING SOCIODEMOGRAPHIC VARIABLES IN A PHARMACY DATASET: APPLYING DATA FROM US CENSUS 2000
	LaFleur J, Ghate S, Ye X
	University of Utah, Salt Lake City, UT, USA

PMC20	METHODS TO SUMMARIZE COMPLICATED DATASETS CONTAINING STRUCTURED, NOMINAL DATA USING SAS
	Zahedi H
	University of Louisville, Louisville, KY, USA
RESEARCH ON METHODS & CONCEPTUAL PAPERS Modeling Studies
PMC21	COST-EFFECTIVENESS SENSITIVITY TO COST-EFFECTIVENESS CORRELATION: A SIMULATION STUDY
	Muston D
	Heron Evidence Development Ltd, Letchworth, Hertfordshire, UK

PMC22	A MODEL TO EXAMINE THE EFFECT OF GUIDELINES ON OUTCOMES RESEARCH
	Baser O1, Wang L2
	1STATinMED Research and University of Michigan, Ann Arbor, MI, USA, 2STATinMED Research, Ann Arbor, MI, USA

PMC23	PREDICTION MODELS FOR TRANSITIONS IN THE ELDERLY USING ADMINISTRATIVE CLAIMS
	Rapp T, Zuckerman IH, Sato M
	University of Maryland Baltimore, Baltimore, MD, USA

PMC24	INVERSE PROBABILITY WEIGHTED RANDOM EFFECT MODELS FOR ESTIMATION OF CENSORED OUTCOMES VARIABLES
	Baser O1, Yuce H2
	1STATinMED Research and University of Michigan, Ann Arbor, MI, USA, 2STATinMED Research and The City University of New York, Brooklyn, NY, USA

PMC25	SENSITIVITY ANALYSIS FOR PROPENSITY SCORE MATCHING
	Baser O1, Gust C2
	1STATinMED Research and University of Michigan, Ann Arbor, MI, USA, 2STATinMED Research, Ann Arbor, MI, USA

PMC26	APPLICATION OF THE FRAMEWORK FOR EVALUATING COMPLEX INTERVENTIONS TO CLUSTER RANDOMIZED TRIALS FOR THE EVALUATION OF DISEASE MANAGEMENT PROGRAMS
	Marchisio S1, Panella M2
	1University Politecnica delle Marche, Ancona, Italy, 2Univerisity of Eastern Piedmont "A. Avogadro", Novara, NO, Italy

PMC27	WITHDRAWN

RESEARCH ON METHODS & CONCEPTUAL PAPERS Patient-Reported Outcomes Studies
PMC28	RASCH PARTIAL CREDIT ANALYSIS OF THE SF-12V2 USING THE 2003 MEDICAL EXPENDITURE PANEL SURVEY (MEPS)
	Gu NY, Doctor JN
	University of Southern California, Los Angeles, CA, USA

PMC29	INTERNATIONAL VALUATION SET FOR EQ-5D HEALTH STATES
	Craig BM1, Busschbach JJ2, Salomon J3
	1Moffitt Cancer Center, Tampa, FL, USA, 2Erasmus Medical Center, Rotterdam, Netherlands, 3Harvard University, Boston, MA, USA

PMC30	A REVIEW AND CRITIQUE OF METHODS FOR MEASURING TEMPORARY HEALTH STATES IN COST-UTILITY ANALYSES
	Wright DR1, Wittenberg E2, Swan JS3, Miksad R4, Prosser L5
	1Harvard School of Public Health, Boston, MA, USA, 2Brandeis University, Waltham, MA, USA, 3Massachusetts General Hospital, Boston, MA, USA, 4Beth Israel Deaconess Medical Center, Boston, MA, USA, 5Harvard Medical School, Boston, MA, USA

PMC31	CONTROLLING MEASUREMENT ERROR OF PATIENT-REPORTED-OUTCOMES DURING THE IMPLEMENTATION STAGE OF CLINICAL TRIALS
	Gnanasakthy A
	Novartis Pharmaceuticals, East Hanover, NJ, USA

PMC32	PREDICTING SF-6D PREFERENCE-BASED UTILITIES USING MEAN SF-36 HEALTH DIMENSION SCORES WHEN PATIENT LEVEL DATA ARE NOT AVAILABLE
	Ara R1, Brazier JE2
	1University of Sheffield, Sheffield, South Yorkshire, UK, 2The University of Sheffield, Sheffield, South Yorkshire, UK

PMC33	PREDICTING A MEAN EQ-5D PREFERENCE-BASED SCORE FROM THE 8 MEAN SF-36 DIMENSION SCORES WHEN INDIVIDUAL DATA IS NOT AVAILABLE
	Ara R1, Brazier JE2
	1University of Sheffield, Sheffield, South Yorkshire, UK, 2The University of Sheffield, Sheffield, South Yorkshire, UK

PMC34	INTERNATIONAL SURVEY ON WTP FOR ONE ADDITIONAL QALY GAIN – HOW MUCH IS THE THRESHOLD OF COST-EFFECTIVENESS ANALYSIS
	Shiroiwa T1, Sung YK2, Fukuda T1, Bae SC2, Tsutani K1
	1The University of Tokyo, Tokyo, Japan, 2Hanyang University College of Medicine, Seoul, South Korea

PMC35	A SYSTEMATIC REVIEW OF APPLICATIONS OF CONJOINT ANALYSIS IN MEDICINE
	Kinter ET1, Bridges JF1, McCormick C2, Kidane L3
	1Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA, 2Johns Hopkins Medical University, Baltimore, MD, USA, 3Johns Hopkins University, Baltimore, MD, USA

PMC36	THE USE OF A MOBILE PHONE FOR ASSESSING MOOD AND PERFORMANCE IN EVERYDAY LIFE
	Tiplady B, Oshinowo B, Thomson J, Drummond GB
	University of Edinburgh, Edinburgh, UK

PMC37	ACCESS TO PATIENT-REPORTED OUTCOME (PRO) INSTRUMENTS AND THEIR TRANSLATIONS IN THE LIGHT OF FDA RECOMMENDATIONS
	Anfray C, Emery MP
	Mapi Research Trust, Lyon, France

PMC38	USE OF A MOBILE PHONE TO ADMINISTER VISUAL ANALOGUE SCALES (VAS)
	Tiplady B1, Cairns W2, Sturdee M2, Oshinowo B2, Thomson J2, Drummond GB2, Wright P2
	1PRO Consulting, Twickenham, London, UK, 2University of Edinburgh, Edinburgh, UK

PMC39	A COMPREHENSIVE PARADIGM TO ESTIMATE MINIMAL CLINICALLY IMPORTANT DIFFERENCES (MCID)
	Treglia M, Mancuso J, Cappelleri J, Bushmakin AG, Pitman V
	Pfizer Inc, Groton, CT, USA

PMC40	PHARMACY STUDENTS' PERCEPTIONS OF HEALTH-RELATED QUALITY OF LIFE FOR MULTIPLE CHRONIC HEALTH STATES MEASURED VIA ALTERNATIVE METHODS FOR UTILITY ASSESSMENT
	Patel RA, Walberg MP
	University of the Pacific, Stockton, CA, USA

PMC41	MAPPING SF-12 TO EUROQOL EQ-5D PREFERENCE SCORES IN THE SPANISH-SPEAKING HISPANIC COMMUNITY IN THE UNITED STATES
	Zarate V1, Chuang LH2, Kind P2
	1Pontificia Universidad Católica de Chile, Santiago, RM, Chile, 2University of York, York, UK

PMC42	METHODOLOGICAL ISSUES WITH THE ANALYSIS OF PREFERENCE-BASED EQ-5D INDEX SCORE
	Li L, Fu AZ
	Cleveland Clinic, Cleveland, OH, USA

PMC43	USE OF BACK TRANSLATION REVIEW IN THE TRANSLATION OF PRO INSTRUMENTS – SOME EXAMPLES
	Gordon-Stables R, Wild D
	Oxford Outcomes Ltd, Oxford, UK

PMC44	IS A LITERAL BACK TRANSLATION IN PRO DOCUMENTS ALWAYS THE BEST OPTION?
	Houchin C1, Wild D2
	1Oxford Outcomes Ltd, Oxford, Oxfordshire, UK, 2Oxford Outcomes Ltd, Oxford, UK

PMC45	EQ-5D + VAS = PRO
	Kind P, Chuang LH
	University of York, York, UK

PMC46	DEVELOPMENT OF A STANDARDIZED CLASSIFICATION SYSTEM FOR THE TRANSLATIONS OF PRO INSTRUMENTS
	Conway K1, Mear I2
	1Mapi Research Trust, Lyon, France, 2Mapi Research Institute, Lyon, France

RESEARCH ON METHODS & CONCEPTUAL PAPERS Study Design Studies
PMC47	EFFICIENCY OF HYBRID APPLICATIONS OF EXACT COVARIATE MATCHING AND PROPENSITY SCORE
	Yang G1, Stemkowski S2, Ernst FR
	Premier Inc, Charlotte, NC, USA

PMC48	SETTING THE OPTIMAL SCREENING TOOL THRESHOLD FOR A CHRONIC UNDERDIAGNOSED ILLNESS: WHOSE BURDEN MATTERS MOST?
	Yu HT, Calimlim B, Dean BB, Dubois R
	Cerner LifeSciences, Beverly Hills, CA, USA

PMC49	TRANSLATING HETEROGENEITY BIAS FROM HEALTH STATUS IN OUTCOMES STUDIES - USING LATENT CLASS CLUSTER ANALYSIS AND LONGITUDINAL DATA
	Ahn J
	University of Southern California, Los Angeles, CA, USA

PMC50	EVIDENCE AND VALUE: IMPACT ON DECISION MAKING - THE EVIDEM FRAMEWORK AND POTENTIAL APPLICATIONS
	Goetghebeur MM, Wagner M, Khoury H, Levitt R, Erickson LJ, Rindress D
	BioMedCom Consultants Inc, Montreal, QC, Canada

PMC51	MEDICATION ADHERENCE: A CONCEPTUAL REVIEW
	Nadkarni A, Kucukarslan SN, Gaither CA, Bagozzi RP
	University of Michigan, Ann Arbor, MI, USA

PMC52	THE DEVELOPMENT OF THE PROGNOSTIC PROPENSITY SCORE: UTILIZED TO PROVIDE PHYSICIANS WITH DETAILED EVIDENCE TO ALLOW FOR OPTIMAL PRESCRIBING
	Stafkey-Mailey DR
	University of Southern California, Los Angeles, CA, USA

PMC53	PREVALENCE OF RESEARCH FOCUSED ON GENETICALLY-LINKED DISORDERS: WHERE HAVE WE BEEN AND WHERE ARE WE GOING?
	Samuels E, Lock K, Karia R, Stoddart SD
	Heron Evidence Development Ltd, Letchworth Garden City, Hertfordshire, UK

PMC54	WITHDRAWN



PMC55	MATRIX MODEL FOR DETERMINING A DRUG'S HEALTH ECONOMIC FOCUS TO OPTIMIZE ITS ECONOMIC VIABILITY
	Hemels M1, Einarson TR2
	1Novo Nordisk, Bagsvaerd, Denmark, 2University of Toronto, Toronto, ON, Canada

CARDIOVASCULAR DISORDERS Clinical Outcomes Studies
PCV1	A MODIFIED RXRISK-V COMORBIDITY INDEX PREDICTS ADHERENCE WITH LIPID LOWERING THERAPY (LLT)
	Ghate S1, LaFleur J1, Charland SL2, Sauer B1
	1University of Utah, Salt Lake City, UT, USA, 2University of Colorado, Boulder, CO, USA

PCV2	STROKE EVENTS IN MANAGED CARE PATIENTS MANAGED ACCORDING TO NATIONAL LIPID TREATMENT GUIDELINES
	Balu S1, Simko RJ1, Burge RT1, Quimbo R2, Cziraky MJ2
	1Abbott Laboratories, Abbott Park, IL, USA, 2HealthCore, Inc, Wilmington, DE, USA

PCV3	SYSTEMATIC REVIEW OF NICARDIPINE IN NEUROVASCULAR CONDITIONS
	Reddy P1, Yeh YC1, Clapp M2, Churchill W3
	1Partners Healthcare, Charlestown, MA, USA, 2Massachusetts General Hospital, Boston, MA, USA, 3Brigham and Women's Hospital, Boston, MA, USA

PCV4	APPROPRIATE UTILIZATION AND COST-ANALYSIS OF ADD-ON EZETIMBE LIPID-LOWERING THERAPY AT THE VETERANS AFFAIRS SAN DIEGO HEALTH CARE SYSTEM (VASDHS)
	Rubin LM, Bounthavong M, Christopher MLD, Morreale AP, Plowman BK, Boggie DT
	Veterans Affairs San Diego Healthcare System (VASDHS), San Diego, CA, USA

PCV5	THE IMPACT OF PHARMACISTS' INTERVENTIONS: SENSITIVITY ON PATIENT OUTCOMES IN HYPERLIPIDEMIA MANAGEMENT
	Machado M, Bajcar J, Nassor N, Einarson TR
	University of Toronto, Toronto, ON, Canada

PCV6	ROLE OF OSTEOPROTEGERIN AND RANKL IN BONE AND VASCULAR CALCIFICATION
	Bakhireva LN1, Laughlin GA2, Bettencourt R2, Barrett-Connor E2
	1University of New Mexico, Albuquerque, NM, USA, 2University of California, San Diego, La Jolla, CA, USA

PCV7	RISK OF HOSPITALIZATION ASSOCIATED WITH BETA-BLOCKER THERAPY IN PATIENTS OF CHRONIC HEART FAILURE AND DIABETES: A MEDICAID STUDY
	Sudharshan L, Sharma M, Obajuluwa T, Chen H
	University of Houston, Houston, TX, USA

PCV8	BLOOD PRESSURE SUCCESS ZONE LONGITUDINAL STUDY OF SUCCESS (BPSZ-BLISS). AN OBSERVATIONAL, MULTI-CENTER STUDY OF THE IMPACT OF THE BPSZ EDUCATIONAL PROGRAM ON BLOOD PRESSURE CONTROL, PERSISTENCE, COMPLIANCE, AND TREATMENT SATISFACTION. ENROLLMENT METRICS AND BASELINE COHORT CHARACTERISTICS
	Payne K1, Ishak KJ1, Caro JJ2, Khan ZM3, Stark K4, Flack JM5, Velázquez EJ6, Nesbitt SD7, Califf R6
	1United BioSource Corporation, Montreal, QC, Canada, 2United BioSource Corporation, Concord, MA, USA, 3Novartis Pharmaceuticals, East Hanover, NJ, USA, 4Novartis Pharmaceuticals Corporation, Florham Park, NJ, USA, 5Wayne State University, Detroit, MI, USA, 6Duke University Medical Center, Durham, NC, USA, 7University of Texas Southwestern Medical Center, Dallas, TX, USA

PCV9	TRENDS IN MORTALITY, LENGTH OF STAY AND READMISSIONS AMONG PATIENTS WITH ACUTE STROKE AT THE NATIONAL HEALTHCARE GROUP, SINGAPORE, 2000 -2006
	Sun Y1, Toh MPHS1, Heng BH1, Venketasubramanian N2, Cheah TSJ1
	1National Healthcare Group, Singapore, Singapore, 2National Neuroscience Institute, Singapore, Singapore

PCV10	EFFECTS OF INTENSIFYING LIPID-ALTERING THERAPY ON CHD EVENTS IN A SECONDARY PREVENTION POPULATION WITH HIGH NON-HDL CHOLESTEROL
	Menzin J1, Zhang B1, Friedman M1, Charland SL2, Burge RT2
	1Boston Health Economics, Inc, Waltham, MA, USA, 2Abbott Laboratories, Abbott Park, IL, USA

PCV11	ASSESSMENT AND QUANTIFICATION OF THE BENEFIT RISK RATIO OF ROSUVASTATIN AND ATORVASTATIN FROM A META-ANALYSIS OF HEAD TO HEAD RANDOMISED CONTROLLED TRIALS
	Wlodarczyk JH1, Smith M2, Sullivan DR3
	1John Wlodarczyk Consulting Services, New Lambton, NSW, Australia, 2AstraZeneca Australia, North Ryde, NSW, Australia, 3Royal Prince Alfred Hospital, CAMPERDOWN, NSW, Australia

PCV12	METHODS FOR INDIVIDUALIZING THE BENEFIT AND HARM OF WARFARIN
	Pereira JA1, Holbrook AM2, Thabane L2, Van Walraven C3, Witt DM4, Delate T4
	1University of Toronto, Toronto, ON, Canada, 2McMaster University, Hamilton, ON, Canada, 3Ottawa Health Research Institute, Ottawa, ON, Canada, 4Kaiser Permanente Colorado, Aurora, CO, USA

PCV13	ANGINA FOLLOWING REVASCULARIZATION - FREQUENCY, PATIENT CHARACTERISTICS AND TIMING
	Kempf J1, Shetty S2, Nelson M2, Buysman E2
	1CV Therapeutics, Palo Alto, CA, USA, 2i3 Innovus, Eden Prairie, MN, USA

PCV14	EVALUATION OF RESISTANT HYPERTENSION IN A USUAL-CARE SETTING
	McAdam-Marx C1, Brixner D1, Ye X1, Sung J2, Kahler K2
	1The University of Utah College of Pharmacy, Salt Lake City, UT, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PCV15	SEASONAL VARIATION OF HEART ATTACKS IN WOMEN
	Kriszbacher I1, Bódis J1, Vas B1, Vas G1, Sebestyén A2, Gulacsi L3, Boncz I1
	1University of Pécs, Pécs, Hungary, 2National Health Insurance Fund Administration, Budapest, Hungary, 3Corvinus University of Budapest, Budapest, Hungary

PCV16	PERMANENT STRESS MAY BE THE TRIGGER OF A HEART ATTACK ON THE FIRST WORK-DAY OF THE WEEK
	Kriszbacher I1, Bódis J1, Betlehem J1, Zsigmond E1, Paska T1, Sebestyén A2, Gulacsi L3, Boncz I1
	1University of Pécs, Pécs, Hungary, 2National Health Insurance Fund Administration, Budapest, Hungary, 3Corvinus University of Budapest, Budapest, Hungary

PCV17	PREDICTING CLINICAL OUTCOMES IN MIXED DYSLIPIDEMIA PATIENTS USING THE FRAMINGHAM RISK AND A NEW RISK EQUATION BASED ON A MANAGED CARE DATABASE: A VALIDATION APPROACH
	Burge RT1, Balu S1, Simko RJ1, Quimbo R2, Cziraky MJ2
	1Abbott Laboratories, Abbott Park, IL, USA, 2HealthCore, Inc, Wilmington, DE, USA

PCV18	FACTORS ASSOCIATED WITH RISK OF METABOLIC SYNDROME FOR US FIRST GENERATION ADOLESCENTS (AGES 12-17)
	Sias S, Hufstader MA, White-Means S
	University of Tennessee Health Science Center, Memphis, TN, USA

PCV19	RESIDUAL DYSLIPIDEMIA ON SIMVASTATIN: POPULATION MODELING OF OPTIMAL LIPID VALUE ACHIEVEMENT WITH ADDED EXTENDED-RELEASE NIACIN VERSUS EZETIMIBE
	Stanek E1, Charland S2
	1None, Thorofare, NJ, USA, 2School of Pharmacy, University of Colorado, Winter Park, CO, USA

PCV20	UPDATING THE RXRISK-V: CREATING A CROSSWALK BETWEEN VA AND FIRSTDATABANK THERAPEUTIC CATEGORIES
	LaFleur J, Ghate S, Sauer B
	University of Utah, Salt Lake City, UT, USA

PCV21	PREVALENCE, AWARENESS AND MANAGEMENT OF HYPERTENSION, DYSLIPIDEMIA, AND DIABETES AMONG UNITED STATES ADULTS AGED 65 AND OLDER
	McDonald M1, Hertz RP1, Unger AN1, Lustik MB2
	1Pfizer Inc, New York, NY, USA, 2Science Applications International Corporation, Reston, VA, USA

PCV22	SIGMOID MAXIMUM EFFECT MODELING OF CORONARY HEART DISEASE DEATH AND MYOCARDIAL INFARCTION RATE VERSUS LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN STATIN SECONDARY PREVENTION TRIALS
	Charland S1, Stanek E2
	1School of Pharmacy, University of Colorado, Winter Park, CO, USA, 2None, Thorofare, NJ, USA

PCV23	MEDICAL CLAIMS FOR GASTROINTESTINAL ADVERSE EVENTS ARE COMMON IN PATIENTS PRESCRIBED CLOPIDOGREL
	Lapuerta P1, Goldsmith M1, Jermano J1, Ollendorf DA2, Cryer B3
	1Cogentus Pharmaceuticals, Menlo Park, CA, USA, 2Pharmetrics, Inc, Watertown, MA, USA, 3Southwestern Medical School, Dallas, TX, USA

PCV24	ASSESSMENT OF SAFETY FOR BROMOCRIPTINE: COMPARISONS OF REPORTING SYSTEMS AND A RETROSPECTIVE COHORT STUDY
	Farwell WR1, Lawler E2, Boulanger L3, Cincotta AH1, Scranton RE1
	1VeroScience LLC, Tiverton, RI, USA, 2VA Boston Healthcare System, Boston, MA, USA, 3Abt Associates Inc, Lexington, MA, USA

PCV25	IMPROVEMENTS IN CARDIOVASCULAR DISEASE OUTCOMES IN MANAGED CARE PATIENTS MANAGED ACCORDING TO NATIONAL LIPID TREATMENT GUIDELINES
	Simko RJ1, Balu S1, Burge RT1, Quimbo R2, Cziraky MJ2
	1Abbott Laboratories, Abbott Park, IL, USA, 2HealthCore, Inc, Wilmington, DE, USA

CARDIOVASCULAR DISORDERS Cost Studies
PCV26	BELGIAN BUDGET IMPACT ANALYSES OF ALISKIREN (TEKTURNA/RASILEZ) IN HYPERTENSION
	Lecomte P1, Lamotte M2, Esposito G2, Annemans L3, Kotchie RW4, Munk VC5, Vincze G5
	1Novartis Pharma, Vilvoorde, Belgium, 2IMS Health, Brussels, Belgium, 3Ghent University, Gent, Belgium, 4IMS Health, London, UK, 5Novartis Pharma AG, Basel, Switzerland

PCV27	COST EFFECTIVENESS STUDIES IN HEART FAILURE: AN UPDATE OF THE LITERATURE
	Shah DH1, Agarwal S1, Ashton C2, Johnson M1
	1University of Houston, Houston, TX, USA, 2University of Alabama, Brimingham, AL, USA

PCV28	CARDIOVASCULAR EVENT DRIVEN ECONOMIC ANALYSIS OF ROSUVASTATIN VERSUS SIMVASTATIN USING PRAGMATIC HEAD-TO-HEAD RCTS WITH SURROGATE END-POINT MEASURES
	Farahani P1, Frial T2, Tea J2
	1McMaster University, Hamilton, ON, Canada, 2AstraZeneca Canada, Mississauga, ON, Canada

PCV29	A COST-EFFECTIVENESS ANALYSIS OF TREATMENT TO LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL GOAL IN HIGH-RISK PATIENTS BASED UPON THE 2004 NATIONAL CHOLESTEROL EDUCATION PROGRAM (NCEP) GUIDELINE UPDATE
	Skora JL, Skrepnek GH, Armstrong EP, Malone DC
	University of Arizona, Tucson, AZ, USA

PCV30	CLOPIDOGREL IS COST-EFFECTIVE COMPARED WITH ASPIRIN IN UNITED KINGDOM PATIENTS WITH A MYOCARDIAL INFARCTION WHO SUBSEQUENTLY SUSTAIN AN ISCHAEMIC STROKE OR PERIPHERAL ARTERIAL DISEASE EVENT
	Stevenson MD1, Rawdin AC1, Karnon JD2, Brennan A1
	1University of Sheffield, Sheffield, UK, 2University of Adelaide, Adelaide, Australia

PCV31	COST-EFFECTIVENESS OF DIFFERENT STRATEGIES FOR DIAGNOSIS OF DEEP VEIN THROMBOSIS
	Patel VA, McGhan WF
	University of the Sciences in Philadelphia, Philadelphia, PA, USA

PCV32	COST-EFFECTIVENESS OF CLINICAL PHARMACY SERVICES ON HYPERLIPIDAEMIC MANAGEMENT IN A PUBLIC HOSPITAL OF HONG KONG
	Lee VWY1, Chung JS1, Lee KK1, Tomlinson B2
	1The Chinese University of Hong Kong, Shatin, Hong Kong, 2The Chinese University of Hong Kong, Hong Kong, China

PCV33	LONG-TERM REDUCTION OF CARDIOVASCULAR EVENTS AND COST-EFFECTIVENESS OF DIFFERENT STATINS AND DOSES IN MEXICO
	Mino D1, Soto H2, Gomez E3, Parcero JJ4, Cortés L5, Zanela O6, Polanco AC2
	1Instituto Mexicano de Seguro Social, México D.F, Mexico, 2AstraZeneca Mexico, Naucalpan, Mexico, 3ISSSTE, Mexico City, Mexico, 4Clinical Cardiologist, Tijuana, BC, Mexico, 5Hospital de Especialidades, CMNO, IMSS, Guadalajara, Jalisco, Mexico, 6Centro de Investigación y Docencia Economicas CIDE A.C, México, Distrito Federal, Mexico

PCV34	THE COST-EFFECTIVENESS OF ALISKIREN AS ADD ON TO LOSARTAN AND OPTIMAL ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION AND NEPHROPATHY IN THE UNITED KINGDOM SETTING
	Palmer JL1, Munk VC2, Kotchie R3, Vincze G2, Charney A4, Tucker D1, Annemans L5
	1IMS Health, Basel, Switzerland, 2Novartis Pharma AG, Basel, Switzerland, 3IMS Health, London, UK, 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 5Ghent University, Gent, Belgium

PCV35	GADOFOSVESET IN THE MANAGEMENT OF PERIPHERAL ARTERIAL OCCLUSIVE DISEASE IN CANADA – A MODEL APPROACH FOCUSING ON DIAGNOSTIC CONFIDENCE
	Hass B1, Rebeira M2, Lungershausen J1, Jaszewski B2, D'Onofrio F2, Kienbaum S3
	1IMS HEALTH, Nuremberg, Germany, 2Bayer HealthCare, Toronto, ON, Canada, 3Bayer Schering Pharma AG, Berlin, Germany

PCV36	SYSTEMATIC REVIEW OF COST-EFFECTIVENESS STUDIES ON DIABETES MEDICATION
	Zhang YJ, Nair RR, Kumar J
	The University of Toledo, Toledo, OH, USA

PCV37	BIATRIAL VERSUS RIGHT ATRIAL APPENDAGE PACING IN BRADYCARDIA TACHYCARDIA SYNDROME
	Rucinski P1, Kutarski A1, Latek MM2, Kaminski B3, Rubaj A1, Wdowiak L1
	1Medical University of Lublin, Lublin, Poland, 2George Mason University, Fairfax, VA, USA, 3Warsaw School of Economics, Warszawa, Poland

PCV38	BOSENTAN IS A COST-EFFECTIVE TREATMENT FOR UNITED KINGDOM PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION OF WHO CLASS III
	Stevenson MD1, MacDonald FC2, Langley J2, Akehurst RL1
	1University of Sheffield, Sheffield, UK, 2Actelion Pharmaceuticals UK, London, UK

PCV39	INDIRECT COMPARISONS OF RIVAROXABAN VS ALTERNATIVE PROPHYLAXES FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM IN PATIENTS UNDERGOING TOTAL HIP OR TOTAL KNEE REPLACEMENT
	Diamantopoulos A1, LeReun C2, Rasul F1, Lees M3, Kubin M4
	1IMS Health HEOR, London, UK, 2Carrigaline, Ireland, 3Bayer HealthCare plc, London, UK, 4Bayer Healthcare AG, Wuppertal, Germany

PCV40	COST-EFFECTIVENESS ANALYSIS OF DRUG-ELUTING STENT VS BARE METAL STENT IN PATIENTS WITH ISCHAEMIC HEART DISEASE IN SOCIAL SECURITY MEXICAN INSTITUTE.
	González-Díaz B1, Contreras-Hernandez I1, Salinas-Escudero G2, Garduño-Espinosa J1, Arguero-Sànchez R3, Castaño-Guerra R3, Farell-Campa J3
	1Social Security Mexican Institute, Mexico City, Mexico, 2Hospital Infantil de México Federico Gomez, Mexico City, Mexico, 3Hospital de Cardiologia Centro Medico Nacional Siglo XXI, Mexico City, Mexico

PCV41	COMPARISON OF COST-EFFECTIVENESS OF POM (PRESCRIPTION ONLY) STATINS; OTC (OVER THE COUNTER) STATIN AND PLANT STEROL / STANOL PRODUCTS FOR PRIMARY CVD (CARDIOVASCULAR DISEASE) PREVENTION IN THE UNITED KINGDOM FROM THE PATIENT'S PERSPECTIVE
	Amirsadri-Naeini M, Jackson PR
	University of Sheffield, Sheffield, South Yorkshire, UK
PCV42	DR
	Kontsevaya A1, Kalinina A2
	1National Research Center of Preventive Medicine, Moscow, Russia, 2National research center of preventive medicine, Moscow, Russia

PCV43	OPTIMIZATION OF DIAGNOSIS AND TREATMENT OF CORONARY ARTERY DISEASE IN CHINA WITH USE OF CORONARY CT ANGIOGRAPHY
	Cheng M1, Hu S2, Lu B2, Higashi MK3, Marelli C4, Li J5, Veenstra DL1
	1University of Washington, Seattle, WA, USA, 2Fuwai Hospital for Cardiovascular Disease, Chinese Academy of Medical Sciences, Beijing, Xicheng District, China, 3GE Healthcare, Wauwatosa, WI, USA, 4GE Healthcare, Buckinghamshire, UK, 5GE Healthcare, Beijing, China

PCV44	RELATIONSHIP BETWEEN THE OBESITY PARADOX AND HEALTH CARE EXPENDITURES IN SUBJECTS WITH CARDIOVASCULAR DISEASE USING THE MEDICAL EXPENDITURE PANEL SURVEY
	Suh HS, Doctor JN
	University of Southern California, Los Angeles, CA, USA

PCV45	ECONOMIC IMPACT OF STROKE-RELATED COMORBID CONDITIONS ON THE TREATMENT OF STROKE: AN ANALYSIS OF MEDICARE BENEFICIARIES IN THE UNITED STATES
	Lee WC1, Pickard AS2, Wilke CT3, Joshi AV4, Yeh YC5, Wang Q1, Pashos CL5
	1Abt Associates, Inc, Bethesda, MD, USA, 2College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA, 3University of Illinois at Chicago, Chicago, IL, USA, 4Novo Nordisk Inc, Princeton, NJ, USA, 5Abt Associates, Inc, Lexington, MA, USA

PCV46	COSTS OF ACUTE MYOCARDIAL INFARCTION IN HUNGARY; 2003-2005
	Karpati K1, Merkely B2, Maurovich Horvat P2, Brodszky V1, Boncz I3, Gulacsi L1
	1Corvinus University of Budapest, Budapest, Hungary, 2Semmelweis University, Budapest, Hungary, 3University of Pécs, Pécs, Hungary

PCV47	MEDICARE OUTLIER PAYMENTS FOR CORONARY ARTERY BYPASS GRAFTING
	Baser O
	STATinMED Research and University of Michigan, Ann Arbor, MI, USA

PCV48	LIKELIHOOD AND COST OF ADVERSE EVENTS IN ATRIAL FIBRILLATION ARE ASSOCIATED WITH CHOICE OF ACUTE CONVERSION THERAPY
	Belz M1, Spalding JR2, Exuzides A3, Adams S4, Colby C3, Noe LL5, Neil N5
	1Group Health Cooperative, Seattle, WA, USA, 2Astellas Pharma US, Deerfield, IL, USA, 3ICON Clinical Research, San Francisco, CA, USA, 4Clinical Research, San Francisco, CA, USA, 5ICON Clinical Research, Highland Park, IL, USA

PCV49	ECONOMIC BURDEN OF VENOUS THROMBOEMBOLISM IN THE GENERAL POPULATION AND AFTER MAJOR ORTHOPAEDIC SURGERY – RESULTS OF A SYSTEMATIC LITERATURE REVIEW
	Steinle T1, Ruppert A2, Lees M3
	1Steinle-Health Economics and Outcomes Research, Munich, Germany, 2IMS Consulting, Cambridge, UK, 3Bayer HealthCare, London, UK

PCV50	UP-TITRATION OF STATIN THERAPY TO MEET CANADIAN TARGET LIPID GOALS: ECONOMIC IMPACT OF TITRATION ASSOCIATED WITH COMPARATIVE EFFICACY OF ROSUVASTATIN, ATORVASTATIN, SIMVASTATIN AND PRAVASTATIN
	Frial T1, Beamer B1, Costa-Scharplatz M2
	1AstraZeneca Canada Inc, Mississauga, ON, Canada, 2AstraZeneca, Södertälje, Sweden

PCV51	A FLEXIBLE TOOL TO ESTIMATE MEDICAL-CARE COSTS FOR STUDY EVENTS IN CARDIOVASCULAR ENDPOINT TRIALS
	Thompson D1, O'Sullivan AK1, Rubin JL1, Nyambose J1, Kuznik A2, Lee F2, Cohen DJ3, Crown W1, Weinstein MC4
	1i3 Innovus, Medford, MA, USA, 2Pfizer Inc, New York, NY, USA, 3Saint-Luke's Mid America Heart Institute, Kansas City, MO, USA, 4Harvard School of Public Health, Boston, MA, USA

PCV52	ECONOMIC IMPACT OF A PHYSICIAN-PHARMACIST COLLABORATIVE CARE INTERVENTION IN PRIMARY CARE FOR PATIENTS WITH DYSLIPIDEMIA: A CLUSTER-RANDOMISED CONTROLLED TRIAL (TEAM STUDY)
	Villeneuve J1, Perreault S1, Blais L1, Berbiche D2, Hudon E2, Lussier MT2, Vanier MC1, Lamarre D1, Genest J3, Lalonde L1
	1University of Montreal, Montreal, QC, Canada, 2Centre de Santé et Services Sociaux de Laval, Laval, QC, Canada, 3McGill University Health Center, Royal-Victoria Hospital, Montreal, QC, Canada

PCV53	DRUG-ELUTING STENTS FROM A MEDICARE PAYER PERSPECTIVE: COST-UTILITY ANALYSIS WITH 4-YEAR CLINICAL META-ANALYSIS DATA
	Bischof M1, Briel M2, Bucher HC2, Nordmann A2
	1University of Basel, Basel, BS, Switzerland, 2University Hospital Basel, Basel, BS, Switzerland

PCV54	THE COST-UTILITY OF ALISKIREN IN THE TREATMENT OF MILD TO MODERATE HYPERTENSION. A CANADIAN HEALTH CARE SYSTEM PERSPECTIVE
	Lee A1, Barry SJ1, Leiter L2, Nanji A3, Annemans L4, Tucker D5, Michaliszyn AF6, Barbeau M6, Vincze G7
	1i3 Innovus, Burlington, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3C-era Medical Clinic, Calgary, AB, Canada, 4Ghent University, Gent, Belgium, 5IMS Health, Basel, Switzerland, 6Novartis Pharmaceuticals Canada Inc, Dorval, QC, Canada, 7Novartis Pharma AG, Basel, Switzerland

PCV55	THIRY-DAY RESOURCE USE DIARY DATA FROM THE BURST STUDY
	Seung SJ1, Mittmann N1, Sharma M2
	1HOPE Research Centre, Toronto, ON, Canada, 2The Ottawa Hospital, Ottawa, ON, Canada

PCV56	VOLUME AND MIX OF CARDIAC X-RAY PROCEDURES ACROSS U.S. HOSPITALS: UTILIZATION DATA TO SUPPORT FINANCIAL DECISIONS
	Jassak S1, Lunacsek O2, Patel P3, Shah M2
	1Wheaton Franciscan Healthcare, Milwaukee, WI, USA, 2Xcenda, Palm Harbor, FL, USA, 3GE Healthcare, Barrington, IL, USA

CARDIOVASCULAR DISORDERS Patient-Reported Outcomes
PCV57	PREVALENCE OF UNDERUTILIZATION OF INITIATED STATIN THERAPY AND RENIN-ANGIOTENSIN SYSTEM BLOCKADE
	Bowen KL, Owerbach J
	Excellus BlueCross BlueShield, Rochester, NY, USA

PCV58	MODELING CARDIOVASCULAR HEALTH OUTCOMES IN MEDICAID HYPERTENSIVE PATIENTS – EFFECT OF PATIENT ADHERENCE
	Gu A, Shaya FT, Weir MR
	University of Maryland School of Pharmacy, Baltimore, MD, USA

PCV59	THE COST AND EFFECTIVENESS OF ADHERENCE-IMPROVING INTERVENTIONS FOR LIPID-LOWERING AND ANTIHYPERTENSIVE DRUGS
	Chapman RH1, Ferrufino C1, Kowal-Podmore S1, Classi P2, Roberts CS2
	1IMS Health, Falls Church, VA, USA, 2Pfizer Inc, New York, NY, USA

PCV60	USING A LONGITUDINAL MODEL TO ANALYZE DRUG COMPLIANCE
	Gause D, Lau H
	Novartis Pharmaceuticals, East Hanover, NJ, USA

PCV61	IMPACT OF PRESCRIPTION COPAY ON ADHERENCE WITH RENIN-ANGIOTENSIN SYSTEM AGENTS IN HEART FAILURE PATIENTS
	Ye X1, Sun SX1, Lee KY1, Dupclay L2, Plauschinat C2
	1Walgreens Health Services, Deerfield, IL, USA, 2Novartis Pharmaceuticals, East Hanover, NJ, USA

PCV62	WITHDRAWN



PCV63	BARRIERS AND MOTIVATORS ASSOCIATED WITH ADHERENCE TO ANTIHYPERTENSIVE MEDICATIONS AND BLOOD PRESSURE CONTROL AMONG AFRICAN AMERICANS FROM ALABAMA
	Salas M
	University of Alabama at Birmingham, Birmingham, AL, USA

PCV64	IMPACT OF STATIN STEP CARE PROGRAM ON PATIENT COMPLIANCE
	Ying X, Jung E, Jiang JZ, Khandelwal NG, Lee KY
	Walgreens Health Services, Deerfield, IL, USA

PCV65	CHANGE IN HEALTH-RELATED QUALITY OF LIFE FOLLOWING NON-FATAL CARDIOVASCULAR EVENTS IN POST-MYOCARDIAL INFARCTION PATIENTS
	Lewis EF1, Li Y2, Pfeffer MA1, Solomon SD1, Weinfurt KP2, Velázquez EJ3, Califf R3, White HD4, Rouleau JL5, Schulman KA2, Reed SD2
	1Brigham and Women's Hospital, Boston, MA, USA, 2Duke Clinical Research Institute, Durham, NC, USA, 3Duke University Medical Center, Durham, NC, USA, 4Auckland City Hospital, Auckland, New Zealand, 5Montreal Heart Institute, Montreal, Quebec, Canada

PCV66	WITHDRAWN

PCV67	RESPONSIVENESS OF PROXY-RATED PREFERENCE-BASED MEASURES OF HEALTH-RELATED QUALITY OF LIFE
	Wilke CT1, Pickard AS1, Feeny DH2, Johnson JA3
	1College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA, 2Kaiser Permanente Center for Health Research, Portland, OR, USA, 3University of Alberta, Edmonton, AB, Canada

PCV68	CLINICAL DETERMINANTS OF SATISFACTION AND HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH CARDIAC DISEASE AND DYSLIPIDEMIA
	Raju AD1, Sansgiry S1, Mirzai-Tehrane M2, Rashid H2, Mortazavi A2, Birtcher K1
	1University of Houston, Houston, TX, USA, 2Kelsey-Seybold Clinic, Houston, TX, USA

PCV69	CONVENIENCE OF THE NEW LONG-ACTING ANTICOAGULANT IDRAPARINUX VERSUS VITAMIN K ANTAGONIST IN PATIENTS WITH ATRIAL FIBRILLATION
	Prins MH1, Leguet P2, Gilet H3, Roborel de Climens A3, Arnould B3
	1Maastricht University, Academic Hospital Maastricht, Maastricht, Netherlands, 2Sanofi-Aventis, Paris Cedex 13, France, 3Mapi Values France, Lyon, France

PCV70	PATIENT ADHERENCE TO CHOLESTEROL TREATMENT (PACT): CANADIAN PHYSICIAN AND PATIENT PERSPECTIVES
	Beamer B, Lukinuk C, Frial T, Corsen D
	AstraZeneca Canada, Mississauga, ON, Canada

PCV71	PSYCHOLOGICAL FACTORS AS PREDICTORS OF CARDIOVASCULAR RISK IN A PROSPECTIVE STUDY COHORT IN THE UNITED KINGDOM
	Timmaraju V1, Gallagher J2
	1PharmArchitecture Limited, London, UK, 2Cardiff University, Cardiff, UK

PCV72	ENHANCING THE EFFECTIVENESS OF COMMUNITY STROKE RISK SCREENING: A RANDOMIZED CONTROL TRIAL
	Anderson RT1, Camacho F1, Kharbanda A2, Iaconi A2, Balkrishnan R3
	1Wake Forest University School of Medicine, Winston Salem, NC, USA, 2The Ohio State University, Columbus, OH, USA, 3The Ohio State University College of Pharmacy, Columbus, OH, USA

PCV73	VALIDATION OF AN ABBREVIATED TREATMENT SATISFACTION QUESTIONNAIRE FOR MEDICATION (TSQM-9) AMONG PATIENTS ON ANTIHYPERTENSIVE MEDICATIONS
	Bharmal M1, Payne K2, Atkinson M3, Gemmen EK4
	1Quintiles, Falls Church, VA, USA, 2United BioSource Corporation, Montreal, QC, Canada, 3University of California San Diego, La Jolla, CA, USA, 4Quintiles Strategic Research & Safety, Falls Church, VA, USA

PCV74	THE IMPACT OF TARGETED MEMBER EDUCATION ON CHOICE OF PREFERRED STATIN THERAPY AFTER A FORMULARY CHANGE
	Cox E, Mager D
	Express Scripts Inc, St. Louis, MO, USA

CARDIOVASCULAR DISORDERS Health Care Use and Policy Studies
PCV75	LOW-DENSITY LIPOPROTEIN APHERESIS FOR THE TREATMENT OF FAMILIAL HYPERCHOLESTEROLEMIA
	Khan T1, Chandra KM2, Pham B3
	1Ontario Ministry of Health and Long-Term Care, Toronto, ON, Canada, 2Program for Assessment of Technology in Health, Hamilton, ON, Canada, 3Toronto Health Economics and Technology Assessment Collaborative, Toronto, ON, Canada
PCV76	LONGITUDINAL ASSESSMENT OF THE CLINICAL UTILITY OF POINT-OF-CARE MEASUREMENT DEVICES FOR DETERMINING THE INTERNATIONAL NORMALIZED RATIO
	Shermock KM1, Lavallee DC2, Conner J3, Fink J4, Bragg L5
	1The Johns Hopkins Hospital, Baltimore, MD, USA, 2University of Maryland School of Pharmacy, Baltimore, MD, USA, 3Berry Consultants, Noblesville, IN, USA, 4The Cleveland Clinic, Cleveland, OH, USA, 5Medina General Hospital, Medina, OH, USA
PCV77	ASSESSMENT OF CONTROL AND TREATMENT PATTERNS IN AN ELDERLY POPULATION WITH COMORBID DIABETES AND HYPERTENSION
	Darah GN1, Prasla K2, Goodman M3, Plauschinat CA2, Plauschinat C4
	1Promedica Physician Group, Sylvania, OH, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3Xcenda, Woodbury, MN, USA, 4Novartis Pharmaceuticals, East Hanover, NJ, USA
PCV78	INTERNATIONAL COMPARISON OF HEALTH CARE RESOURCES AND QUALITY OF LIFE IN ACUTE CORONARY SYNDROME PATIENTS IN 2007: RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL STUDY (APTOR)
	Bakhai A1, Iniguez A2, Ferrieres J3, Needs N4, Schmitt C4, Sartral M5, Zeymer U6
	1Barnet & Chase Farm NHS Trust, Barnet, UK, 2Hospital Meixoeiro, Vigo, Spain, 3CHU Rangueil, 31059 Toulouse, France, 4Eli Lilly and Company Ltd, Windlesham, Surrey, UK, 5Eli Lilly and Company Ltd, Suregnes, Paris, France, 6Institute for MI Research, Ludwigshafen, Germany
PCV79	PHYSICIAN CHARACTERISTICS ASSOCIATED WITH STROKE RELATED OUTPATIENT CARE UTILIZATION: ANALYSIS OF THE NATIONAL AMBULATORY MEDICAL CARE SURVEY DATA 2000-2005
	Karve S, Levine D, Balkrishnan R
	The Ohio State University, Columbus, OH, USA
PCV80	NATIONAL ESTIMATES OF ENROLLMENT IN DISEASE STATE MANAGEMENT PROGRAMS IN THE UNITED STATES
	Kalsekar ID, Flasch S, Nesnidal K
	Butler University, Indianapolis, IN, USA
PCV81	ASSESSING THE IMPACT OF INCORPORATING PATIENT KNOWLEDGE AND BELIEFS INTO ANTICOAGULATION THERAPY MANAGEMENT SERVICES
	Lavallee DC1, Mullins CD1, Haines ST1, Pradel FG1, Palumbo FB1, Tommasello AC1, Winston RA2
	1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Bon Secours Baltimore Health System, Baltimore, MD, USA
PCV82	EVALUATION OF THE EFFECT OF ACUTE DECOMPENSATED HEART FAILURE GUIDELINES IN COMMUNITY HOSPITALS
	Perez A1, Schumock GT1, DiDomenico R1, Theobald JC2, Wojtynek JE3
	1University of Illinois at Chicago, Chicago, IL, USA, 2Consorta Inc, Schaumburg, IL, USA, 3ProCE, Inc, Bartlett, IL, USA
PCV83	GENDER DISPARITIES IN THE UTILIZATION OF MYOCARDIAL PERFUSION IMAGING
	Gao X1, Spalding JR2, Denevich S3, Reddy P3
	1Abt Associates Inc, Bethesda, MD, USA, 2Astellas Pharma US, Deerfield, IL, USA, 3Abt Associates Inc, Lexington, MA, USA
PCV84	HEALTH CARE UTILIZATION ASSOCIATED WITH DEPRESSION FOLLOWING THROMBOTIC CARDIOVASCULAR EVENTS IN ELDERLY MEDICARE BENEFICIARIES
	Blanchette CM1, Simoni-Wastila L2, Shaya FT2, Orwig D2, Noel J2, Stuart B2
	1Lovelace Respiratory Research Institute, Albuquerque, NM, USA, 2University of Maryland, Baltimore, MD, USA
PCV85	IMPACT OF MEDICARE PART D IMPLEMENTATION ON STATIN UTILIZATION AND MARKET SHARE IN STATE MEDICAID PROGRAMS
	Nag A1, Lawson KA2
	1The University of Texas at Austin, Austin, TX, USA, 2University of Texas at Austin, Austin, TX, USA
PCV86	PATTERNS OF DIURETIC USE IN MULTI-DRUG ANTI-HYPERTENSIVE REGIMENS IN THE POST ALLHAT ERA
	Parikh NM1, Singh H2, Ashton C3, Sharma M1, Yadav R1, Walder A4, Johnson M5
	1University of Houston, Houston, TX, USA, 2Michael E. DeBakey Veterans Affairs Medical Center; Baylor College of Medicine, Houston, TX, USA, 3University of Alabama, Birmingham, AL, USA, 4Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA, 5University of Houston; Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA
PCV87	PHYSICIAN AND PATIENT FACTORS PREDICTING THE PRESCRIBING OF STATINS IN HYPERTENSION AND DIABETES
	Bodhani A, Li C, Martin BC
	University of Arkansas for Medical Sciences, Little Rock, AR, USA
PCV88	OLD HABITS DIE HARD: A NATIONWIDE UTILIZATION STUDY OF CALCIUM CHANNEL BLOCKERS IN TAIWAN
	Chen TJ1, Chou LF2, Hwang SJ1
	1Taipei Veterans General Hospital, Taipei, Taiwan, 2National Chengchi University, Taipei, Taiwan
PCV89	PRE AND POST STROKE STATIN USE AND ASSOCIATED HEALTH CARE COSTS AMONG ELDERLY STROKE SURVIVORS
	Karve S1, Levine D1, Anderson RT2, Camacho F2, Balkrishnan R1
	1The Ohio State University, Columbus, OH, USA, 2Wake Forest University School of Medicine, Winston Salem, NC, USA
PCV90	DISPARITIES IN MEDICAL EXPENDITURES AND UTILIZATION AMONG HYPERTENSIVE MEN AND WOMEN IN THE UNITED STATES
	Basu R, Franzini L, Krueger PM, Lairson DR
	University of Texas School of Public Health, Houston, TX, USA
PCV91	PATIENT INSURANCE AND MEDICATION CHOICE FOR HYPERCHOLESTEROLEMIA
	Epstein AJ1, Rathore SS1, Alexander GC2, Ketcham JD3
	1Yale University, New Haven, CT, USA, 2University of Chicago, Chicago, IL, USA, 3Arizona State University, Tempe, AZ, USA
PCV92	THE HEALTH AND ECONOMIC IMPACT OF SWITCHING FROM ATORVASTATIN TO SIMVASTATIN IN THE US
	Liew D1, Kuznik A2, Webb K3, Roberts CS2
	1The University of Melbourne, Melbourne, Victoria, Australia, 2Pfizer Inc, New York, NY, USA, 3Pfizer Inc, Tadworth, Surrey, UK
PCV93	LIFETIME MEDICAL EXPENDITURES AMONG HYPERTENSIVE MEN AND WOMEN IN THE UNITED STATES
	Basu R, Krueger PM, Franzini L, Lairson DR
	University of Texas School of Public Health, Houston, TX, USA
PCV94	PREDICTING HIGH COSTS IN MEDICARE BENEFICIARIES WITH HEART FAILURE
	Curtis LH1, Greiner MA1, Shea AM1, Hammill BG1, Hernandez AF1, Schulman KA2
	1Duke University, Durham, NC, USA, 2Duke Clinical Research Institute, Durham, NC, USA
PCV95	IMPACT OF ADOPTION OF NEW ANTIHYPERTENSIVE DRUGS ON THE HEALTH CARE UTILIZATION IN HYPERTENSIVE PATIENTS
	Ganguli A, Hong SH, Wingate L
	University of Tennessee, Memphis, TN, USA
PCV96	THE EFFECT OF MEASUREMENT ERROR FROM POINT-OF-CARE INR DEVICES ON WARFARIN DOSING DECISIONS
	Shermock KM1, Lavallee DC2, Connor J3, Streiff M4
	1The Johns Hopkins Hospital, Baltimore, MD, USA, 2University of Maryland School of Pharmacy, Baltimore, MD, USA, 3Berry Consultants, Noblesville, IN, USA, 4The Johns Hopkins Medical Institutions, Baltimore, MD, USA
PCV97	IS THERE A LEARNING CURVE ASSOCIATED WITH EXERCISE TRAINING IN PATIENTS WITH HEART FAILURE?
	Li Y1, Friedman JY1, Compton KL2, Tzeng JP3, Schulman KA1, Reed SD1
	1Duke Clinical Research Institute, Durham, NC, USA, 2University of North Carolina, Durham, NC, USA, 3University of North Carolina, Chapel Hill, NC, USA
PCV98	THE EFFECTS OF STEP THERAPY: LOOKING BEYOND IMPACTS ON PRESCRIBING RATES AND COSTS
	Mark TL1, Gibson TB2, McGuigan K3
	1Thomson Healthcare, Washington, DC, USA, 2Thomson Medstat, Ann Arbor, MI, USA, 3Pfizer Global Pharmaceuticals, New York, NY, USA
PCV99	THE FIRST MOVER STRIKES AGAIN. COST-EFFECTIVENESS OF STATINS AND PRESCRIBING BEHAVIOR IN PORTUGAL
	Pinto CG1, Miguel LS2, Paquete AT2
	1Instituto Superior de Economia e Gestão, Technical University of Lisbon, Lisboa, Portugal, 2Research Centre on the Portuguese Economy - CISEP, Lisboa, Portugal
PCV100	THE EFFECTIVENESS OF A PATIENT AND PHYSICIAN EDUCATIONAL PROGRAM IN INITIATING STATIN THERAPY AMONG DIABETICS
	Patel BV1, Ghomrawi H2, Gao S1
	1MedImpact Healthcare Systems, Inc, San Diego, CA, USA, 2Cornell University, New York, NY, USA
PCV101	WITHDRAWN

PCV102	THE ASSESSING CARDIOVASCULAR TARGETS (ACT ‘07) PROGRAM: PRELIMINARY RESULTS FROM A PRACTICE REFLECTIVE ASSESSMENT ACROSS CANADA
	Beamer B, Frial T, Corsen D, Long J
	AstraZeneca Canada, Mississauga, ON, Canada
PCV103	THE PATIENT SAFETY STANDARDS OF ACUTE STROKE MANAGEMENT IN HUNGARY
	Betlehem J1, Kriszbacher I1, Oláh A1, Boncz I1, Sebestyén A2, Marton J1, Nagy G1, Gulacsi L3, Bódis J1, Veres R4
	1University of Pécs, Pécs, Hungary, 2National Health Insurance Fund Administration, Budapest, Hungary, 3Corvinus University of Budapest, Budapest, Hungary, 4BAZ County Hospital, Miskolc, Hungary
PCV104	RELATIONSHIP BETWEEN QUALITY OF CARE AND EXCESSIVE COST FOR MEDICARE PATIENTS UNDERGOING LOWER EXTREMITY BYPASS SURGERY
	Baser O
	STATinMED Research and University of Michigan, Ann Arbor, MI, USA
PCV105	IMPACT OF GUIDELINES FOR TREATMENT AND PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN COMMUNITY HOSPITALS
	Vats V1, Nutescu EA1, Theobald JC2, Wojtynek JE3, Schumock GT1
	1University of Illinois at Chicago, Chicago, IL, USA, 2HealthTrust Purchasing Group, Brentwood, TN, USA, 3ProCE, Inc, Bartlett, IL, USA

DIABETES/ENDOCRINE DISORDERSClinical Outcomes Studies
PDB1	EXENATIDE UTILIZATION AND EFFECTIVENESS IN A HEALTH PLAN POPULATION
	Schroeder B1, Misurski D2, Wade R3, Quimbo R3, Nielsen L1, Fabunmi R1, Wintle M1
	1Amylin Pharmaceuticals, Inc, San Diego, CA, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 3HealthCore, Inc, Wilmington, DE, USA
PDB2	HBA1C GOAL ATTAINMENT IN RELATION TO DOSE AMONG DIABETES PATIENTS USING METFORMIN
	Penning-van Beest FJ1, Wolffenbuttel BH2, Herings RM1
	1PHARMO Institute, Utrecht, Netherlands, 2University Medical Centre Groningen, Groningen, Netherlands
PDB3	WITHDRAWN

PDB4	ESTIMATION OF STUDY POPULATION SIZE FOR EFFECTIVENESS OUTCOMES AT 6 AND 12 MONTHS VIA ELECTRONIC MEDICAL RECORDS
	McAdam-Marx C, Brixner D, Oberg B
	The University of Utah College of Pharmacy, Salt Lake City, UT, USA
PDB5	WITHDRAWN

PDB6	WITHDRAWN

PDB7	EVALUATION OF INSULIN CONTAINING ANTI-DIABETIC REGIMENS IN HIGH-RISK CARDIOVASCULAR PATIENTS WITH A PRE-TREATMENT A1C MEASUREMENT GREATER THAN 9%
	Livengood K
	University of Southern California, Los Angeles, CA, USA
PDB8	DEFINING HYPOGLYCEMIA AND ASSESSING ITS AFFECT ON OUTCOMES IN THE HOSPITAL SETTING
	Curkendall SM1, Alexander CM2, Haidar T1, Natoli JL3, Dubois RW3, Nathanson BH4
	1Cerner LifeSciences, Vienna, VA, USA, 2Merck, White House Station, NJ, USA, 3Cerner LifeSciences, Beverly Hills, CA, USA, 4OptiStatim, Longmeadow, MA, USA
PDB9	TYPE 2 DIABETES IN YOUTH: 2002 AND 2006 PREVALENCE AND OBESITY IN A PRIMARY CARE SETTING
	McAdam-Marx C1, Brixner D1, Field R2, Metraux S2
	1The University of Utah College of Pharmacy, Salt Lake City, UT, USA, 2The University of the Sciences in Philadelphia, Philadelphia, PA, USA
PDB10	OBESITY IS MORE PREVALENT AMONG ABORIGINALS WITH DIABETES AS COMPARED TO ALL CANADIANS WITH DIABETES
	Beard K1, Folia C1, Frial T2, Liovas A3
	1Agro Health Associates, Burlington, ON, Canada, 2AstraZeneca Canada, Mississauga, ON, Canada, 3AstraZeneca Canada Inc, Mississauga, ON, Canada
PDB11	PREVALENCE OF AND RISK FACTORS FOR HOSPITALIZATIONS IN PATIENTS WITH TYPE 2 DIABETES IN SOUTH KOREA
	Kim CM1, Choi IS2, Jung JC3, Barone JA2, Kim CM4, Suh DC2
	1Catholic University, Sucho-gu, Seoul, South Korea, 2Rutgers University, Piscataway, NJ, USA, 3Korea National Health Insurance Corporation, Mapo-gu, Seoul, South Korea, 4Merck Global Human heath, Whitehouse Station, NJ, USA
PDB12	CLINICAL AND ECONOMIC OUTCOMES RELATED TO A PAY-FOR-PERFORMANCE PROGRAM
	Marehbian J, Legorreta G, Hoffman J, Latino C, Chen JY
	Health Benchmarks, Inc, Woodland Hills, CA, USA
PDB13	PREDICTING INPATIENT HOSPITALIZATION RISKS FOR MEDICAID DIABETES PATIENTS
	Zeng F, Patel BV, Gao S
	MedImpact Healthcare Systems, Inc, San Diego, CA, USA

DIABETES/ENDOCRINE DISORDERS Cost Studies
PDB14	BUDGET IMPACT OF ADDING FIXED-DOSE COMBINATION OF PIOGLITAZONE PLUS GLIMEPIRIDE TO A FORMULARY PLAN OVER A THREE-YEAR TIME FRAME
	Lobo F1, Thomas S1, Sill B1, Hede S1, Pandya B2
	1Takeda Pharmaceuticals North America, Deerfield, IL, USA, 2Takeda Global Research and Development Center, Inc, Deerfield, IL, USA
PDB15	COSTS OF PEN (NOVOPEN® 3) VERSUS SYRINGE IN THE TREATMENT OF DIABETES MELLITUS TYPE 2 - A PHARMACOECONOMIC STUDY FROM THE SLOVAK REPUBLIC
	Bielik J1, Ehsan N2, Lacka J3, Pastucha M4
	1Trencin University, Trenčín, Slovak Republic, 2Private diabetology out-clinic dpt, Nové Mesto nad Váhom, Slovak Republic, 3Novo Nordisk A/S, Bratislava, Slovak Republic, 4General Health Insurance Company, Trencin, Slovak Republic
PDB16	THE BUDGET IMPACT OF APIDRA® (INSULIN GLULISINE) REIMBURSEMENT IN POLAND
	Walczak J1, Mucha J1, Augustynska J1, Gierczynski J2, Nogas G1
	1Arcana Institute, Cracow, Poland, 2Sanofi-Aventis sp. z o.o, Warszawa, Poland
PDB17	AN EVALUATION OF EXPECTED WASTE OF GROWTH HORMONE PEN DEVICES AND AN ELECTRONIC GROWTH HORMONE DELIVERY DEVICE
	Edwards NC1, Phillips AL2, Kreher NC2, Meletiche DM2
	1Health Services Consulting Corporation, Boxborough, MA, USA, 2EMD Serono, Inc, Rockland, MA, USA
PDB18	COMPARISON OF RESOURCES UTILIZATION (RU) AND COST IN DRUG NAÏVE TYPE 2 DIABETES (T2D) PATIENTS TREATED WITH ROSIGLITAZONE (RSG) VS. SULFONYLUREA (SU) MONOTHERAPY
	Duh MS1, Gosselin A2, Beaulieu N1, Arana LM1, Arondekar B3
	1Analysis Group, Inc, Boston, MA, USA, 2Groupe d'Analyse, Ltée, Montréal, QC, Canada, 3GlaxoSmithKline, Philadelphia, PA, USA
PDB19	ECONOMIC EVALUATION OF SOMATROPIN (NORDITROPIN) FOR THE TREATMENT OF SHORT CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA)
	Christensen T1, Buckland AG2, Bentley A2, Djuurhus C1, Wing C2
	1Novo Nordisk A/S, Bagsværd, Denmark, 2Abacus International, Bicester, UK
PDB20	COST-EFFECTIVENESS OF INSULIN DETEMIR COMPARED TO NPH INSULIN FOR TYPE 1 DIABETES MELLITUS (T1DM) IN THE CANADIAN PAYER SETTING: MODELING ANALYSIS USING A RANDOMIZED CONTROLLED TRIAL
	Minshall ME1, Tunis SL1, Conner C2, McCormick JI3, Kapor J4, Groleau D4
	1IMS Health, Noblesville, IN, USA, 2Novo Nordisk, Princeton, NJ, USA, 3McKesson Phase 4 Solutions, Toronto, ON, Canada, 4Novo Nordisk, Mississauga, ON, Canada
PDB21	COST-EFFECTIVENESS OF INSULIN DETEMIR COMPARED TO NPH INSULIN FOR TYPE 2 DIABETES MELLITUS (T2DM) IN THE CANADIAN PAYER SETTING: MODELING ANALYSIS USING AN OBSERVATIONAL STUDY
	Minshall ME1, Tunis SL1, Conner C2, McCormick JI3, Kapor J4, Groleau D4
	1IMS Health, Noblesville, IN, USA, 2Novo Nordisk, Princeton, NJ, USA, 3McKesson Phase 4 Solutions, Toronto, ON, Canada, 4Novo Nordisk, Mississauga, ON, Canada
PDB22	COST-EFFECTIVENESS ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INJECTION VS. MULTIPLE DAILY INJECTIONS IN TYPE 1 DIABETES PATIENTS: AN INTERNATIONAL COMPARISON
	Graham C1, Lynch P1, St. Charles M2, Minshall M2
	1Medtronic Diabetes, Northridge, CA, USA, 2IMS Health, Noblesville, IN, USA
PDB23	COST-EFFECTIVENESS ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INJECTION VS. MULTIPLE DAILY INJECTIONS IN TYPE 1 DIABETES PATIENTS: A CANADIAN PERSPECTIVE
	St. Charles M1, Sadri H2, Minshall M1
	1IMS Health, Noblesville, IN, USA, 2Medtronic of Canada, Ltd, Mississauga, ON, Canada
PDB24	LONG-TERM CLINICAL AND COST OUTCOMES OF TREATMENT WITH INSULIN DETEMIR PLUS INSULIN ASPART IN TYPE 1 DIABETES PATIENTS IN THE CZECH SETTING; DATA FROM THE PREDICTIVE STUDY
	Clegg JP1, Valentine WJ1, Rychna K2, Honka M3, Doležal T4
	1IMS, Allschwil, Switzerland, 2Novo Nordisk s.r.o, Praha 6, Czech Republic, 3Faculty Hospital Ostrava, Ostrava, Czech Republic, 4Charles University in Prague, Prague 10, Czech Republic
PDB25	COSTS AND EFFECTIVENESS OF INSULIN VS. ROSIGLITAZONE IN TYPE 2 DIABETES AFTER METFORMIN MONOTHERAPY FAILURE
	Skoupá J1, Cerna V1, Rausova V2, Pavlikova P2
	1Pharma Projects, Prague, Czech Republic, 2GlaxoSmithKline, Prague, Czech Republic
PDB26	ECONOMIC EVALUATION OF THE TREATMENT WITH QUINAGOLIDE IN PATIENTS WITH HYPERPROLACTINAEMIA, TUMOUR REDUCTION
	Mendez MT
	Ferring Pharmaceuticals, Estado de Mexico, Mexico
PDB27	THE COST-EFFECTIVENESS OF INSULIN GLULISINE IN TYPE 2 DIABETES IN POLAND
	Walczak J1, Dardzinski W1, Kusy M1, Lis J2, Nogas G1
	1Arcana Institute, Cracow, Poland, 2Sanofi-Aventis sp. z o.o, Warszawa, Poland
PDB28	COST-EFFECTIVENESS ANALYSIS OF DOPAMINE AGONISTS FOR THE TREATMENT OF INFERTILITY ASOCIATED TO HYPERPROLACTINEMIA IN MEXICO
	Guillen-González S1, Diez-Canseco F1, Zapata L2, Vega-Hernández GY3, Rivas R2, Ramírez H4, Mould-Quevedo J3, Davila-Loaiza G3
	1ISSSTE-Hospital 20 de Noviembre, Mexico City, Mexico, 2Guia Mark, México, DF, Mexico, 3Pfizer Mexico, Mexico City, Mexico, 4Guiamark SC, Mexico City, Mexico
PDB29	PHARMACOECONOMIC EVALUATION OF CABERGOLINE FOR THE MANAGEMENT OF HYPERPROLACTINEMIA CAUSED BY HYPOPHYSEAL MICROADENOMA IN MEXICO
	Guillen-González M1, Diez-Canseco F2, Zapata L3, Vega-Hernández GY4, Rivas R3, Ramírez H5, Mould-Quevedo J6, Davila-Loaiza G6
	1ISSSTE-Hospital 20 de Noviembre, DF, Mexico City, Mexico, 2ISSSTE- Hospital 20 de Noviembre, DF, Mexico City, Mexico, 3Guia Mark, México, DF, Mexico, 4Pfizer Mexico, DF, Mexico City, Mexico, 5Guiamark SC, DF, Mexico City, Mexico, 6Pfizer Mexico, Mexico City, Mexico
PDB30	A MODELLED COST-EFFECTIVENESS ANALYSIS OF SWITCHING PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES TO INSULIN DETEMIR FROM ORAL ANTIDIABETICS OR NPH IN THE AUSTRIAN SETTING; DATA FROM THE PREDICTIVE STUDY
	Stechemesser L1, Weitgasser R1, Hofmann M1, Aagren M2, Mihaljevic R3
	1St.Johanns Spital, Salzburg, Austria, 2Novo Nordisk A/S, Virum, Denmark, 3Novo Nordisk Pharma GmbH, Wien, Austria
PDB31	COST-EFFECTIVENESS OF DETEMIR VERSUS NPH FOR TYPE 1 DIABETES PATIENTS TREATED WITH BASAL-BOLUS THERAPY IN PORTUGAL
	Silva C1, Alves C1, Negreiro F1, Fonseca MA2, Aagren M3
	1Eurotrials, Lisboa, Portugal, 2Novo Nordisk Lda, Paço de Arcos, Portugal, 3Novo Nordisk A/S, Virum, Denmark
PDB32	ECONOMIC EVALUATION OF LONG TERM SOMATOSTATIN ANALOGS IN THE TREATMENT OF ACROMEGALY IN MEXICO
	Salinas Escudero G1, Idrovo J2, Rivas R2, Zapata L2
	1Hospital Infantil de México Federico Gómez, México DF, Distrito Federal, Mexico, 2Guia Mark, Mexico, DF, Mexico
PDB33	COST MINIMIZATION ANALYSIS OF DIFFERENT GROWTH HORMONE DEVICES BASED ON TIME-AND-MOTION SIMULATIONS
	Nickman NA1, Haak SW1, Harald EA1, Holtorf AP1, Joshi AV2, Kim J1, Brixner D1
	1University of Utah, Salt Lake City, UT, USA, 2Novo Nordisk Inc, Princeton, NJ, USA
PDB34	ASSESSING DIFFERENCES IN UTILIZATION AND COSTS BETWEEN INSULIN DETEMIR (LEVEMIR®) AND INSULIN GLARGINE (LANTUS®) USERS
	Borah B1, Alemayehu B2, Henk HJ1, Forma FM2
	1i3 Innovus, Eden Prairie, MN, USA, 2Novo Nordisk, Inc, Princeton, NJ, USA
PDB35	CLINICAL AND ECONOMIC CHARACTERISTICS OF PATIENTS WITH DIABETIC NEUROPATHY
	Zhao Y, Ye W, Le TK, Boye KS, Holcombe J, Hall J, Swindle R
	Eli Lilly and Company, Indianapolis, IN, USA
PDB36	HEALTH SERVICE COSTS AND RESOURCE UTILIZATION AMONG MANAGED CARE ENROLLEES WITH GOUT AND RENAL DISEASE
	Riedel AA1, Fuldeore MJ2, Braun BB3, Krishnan E4
	1i3Innovus, Eden Prairie, MN, USA, 2TAP Pharmaceuticals Products Inc, Lakeforest, IL, USA, 3i3 Innovus, Eden Prairie, MN, USA, 4University of Pittsburgh, Pitttsburgh, PA, USA
PDB37	FACTORS ASSOCIATED WITH HEALTH CARE COSTS AMONG ELDERLY PATIENTS WITH DIABETIC NEUROPATHY
	Boulanger L1, Zhao Y2, Bao Y1, Cai C1, Ye W2, Russell MW1
	1Abt Associates Inc, Lexington, MA, USA, 2Eli Lilly and Company, Indianapolis, IN, USA
PDB38	PREVALENCE OF OTHER DIABETES-ASSOCIATED COMPLICATIONS AND ITS IMPACT ON HEALTH CARE CHARGES AMONG PATIENTS WITH DIABETIC NEUROPATHY
	Zhao Y, Ye W, Boye KS, Holcombe J, Hall J, Swindle R
	Eli Lilly and Company, Indianapolis, IN, USA
PDB39	FACTORS ASSOCIATED WITH HIGH TREATMENT CHARGES IN PATIENTS WITH DIABETIC NEUROPATHY
	Ye W, Zhao Y, Swindle R
	Eli Lilly and Company, Indianapolis, IN, USA
PDB40	WITHDRAWN

PDB41	MEDICAL CARE OF PATIENTS WITH DIABETIC NEUROPATHY: IMPACT OF TYPE 1 DIABETES AND PRESENCE OF OTHER DIABETES-RELATED COMPLICATIONS
	Zhao Y, Ye W, Boye KS, Holcombe J, Hall J, Bledsoe S, Swindle R
	Eli Lilly and Company, Indianapolis, IN, USA
PDB42	COST OF ILLNESS STUDY OF TYPE 2 DIABETES MELLITUS IN LATIN AMERICA
	Gonzalez JC1, Einarson TR2, Walker JH3
	1Merck Sharp & Dohme, Bogota, Colombia, 2University of Toronto, Toronto, ON, Canada, 3Brock University, Faculty of Business, St. Catharines, ON, Canada
PDB43	DETERMINANTS OF THE ECONOMIC BURDEN OF DIABETES HOSPITALIZATIONS IN TENNESSEE
	White-Means S1, Everett BL1, Brown LT1, Walker GD2, Dong Z1
	1University of Tennessee Health Science Center, Memphis, TN, USA, 2University of Tennessee, Memphis, TN, USA
PDB44	COST-EFFECTIVENESS OF THE USE OF ANGIOTENSIN-II-RECEPTER BLOCKERS IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY IN JAPAN
	Ikeda S1, Kobayashi M2, Makino H3
	1International University of Health and Welfare, Ohtawara, Tochigi, Japan, 2Crecon Research and Consulting Inc, Shibuya-ku, Tokyo, Japan, 3Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama, Japan
PDB45	CANADIAN COST UTILITY ANALYSIS COMPARING EXENATIDE VERSUS INSULIN GLARGINE IN PATIENTS WITH TYPE TWO DIABETES
	Coyle D1, Coyle K2, Valentine WJ3, Lee JB4, Kisswani R5, Boye KS6
	1University of Ottawa, Ottawa, ON, Canada, 2Coyle Consultancy, Ottawa, ON, Canada, 3IMS Health, Basel, Switzerland, 4Eli Lilly Canada, Inc, Toronto, ON, Canada, 5McMaster University, Hamilton, ON, Canada, 6Eli Lilly and Company, Indianapolis, IN, USA
PDB46	WITHDRAWN

PDB47	WITHDRAWN

PDB48	LOST PRODUCTIVITY ASSOCIATED WITH TYPE 1 AND TYPE 2 DIABETES IN A COMMERCIALLY-INSURED POPULATION
	Durden ED1, Alemayehu B2, Forma F2
	1Thomson Medstat, Cambridge, MA, USA, 2Novo Nordisk, Inc, Princeton, NJ, USA
PDB49	INFLUENCE OF FAMILY STRUCTURE ON EMERGENCY ROOM UTILIZATION OF DIABETIC MOTHERS
	Wingate L, Wang J, Hong SH, Ganguli A, White-Means S
	University of Tennessee Health Science Center, Memphis, TN, USA
PDB50	INCREASED HOSPITALIZATIONS BY CHILDREN WITH TYPE 2 DIABETES
	Kim SH
	Florida International University, Miami, FL, USA

DIABETES/ENDOCRINE DISORDERSPatient-Reported Outcomes
PDB51	A RESTROSPECTIVE ANALYSIS OF MEDICATIONS ADHERENCE AND ASSOCIATED HEALTH CARE COST FOR THE DIABETIC PATIENTS
	Jing Y1, Sun SX2, Lee KY2, Ye X2, Huang Z2
	1University of Cincinnati, Cincinnati, OH, USA, 2Walgreens Health Services, Deerfield, IL, USA
PDB52	SYSTEMATIC REVIEW OF ADHERENCE, COMPLIANCE AND QUALITY OF LIFE IN TYPE 2 DIABETES PATIENTS
	Kumar J1, Nair R2
	1University of Toledo, Toledo, OH, USA, 2The University of Toledo, Toledo, OH, USA
PDB53	WITHDRAWN


PDB54	DEVELOPMENT OF A CLASSIFICATION SYSTEM FOR A DIABETES-SPECIFIC PREFERENCE-BASED MEASURE OF HEALTH
	Sundaram M, Smith MJ, Nath C
	West Virginia University, Morgantown, WV, USA
PDB55	WITHDRAWN

PDB56	PREFERENCES FOR ORAL ANTIDIABETIC AGENTS AMONG PEOPLE WITH TYPE 2 DIABETES
	Hauber AB1, Mohamed AF1, Johnson FR1, Falvey H2, Snyder E2
	1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novartis Pharma AG, Basel, Switzerland
PDB57	CONTENT DEVELOPMENT FOR A NEW INSTRUMENT TO ASSESS PATIENT AND PARENT PREFERENCE FOR GROWTH HORMONE REPLACEMENT THERAPY DELIVERY DEVICES
	Stephens JM1, Carpiuc KT1, Gold KF2, Altman P3, Germak J3, Joshi AV3
	1Pharmerit North America LLC, Bethesda, MD, USA, 2Harvard University, Cambridge, MA, USA, 3Novo Nordisk Inc, Princeton, NJ, USA
PDB58	ASSOCIATION BETWEEN THE DIABETES-39 (DM-39) AS A PATIENT REPORTED OUTCOME (PRO) AND HBA1C IN A CLINICAL TRIAL INVOLVING INSULIN THERAPY
	Lee LJ1, Hayes RP1, Helbers L2, Jezorwski JE2, Sun P3, Buesching DP1
	1Eli Lilly and Company, Indianapolis, IN, USA, 2Omnicare Clinical Research, King of Prussia, PA, USA, 3Kailo Research Group, Indianapolis, IN, USA
PDB59	IMPACT OF DOCTORS' INSTRUCTIONS ON LIFESTYLE BEHAVIORS AMONG DIABETES POPULATION IN USA
	Guo JD, Root MM, Hu G
	Biosignia Inc, Durham, NC, USA
PDB60	DISCREPANCIES BETWEEN IMPORTANCE AND EVALUATION OF INSULIN DELIVERY SYSTEM (IDS) FEATURES CONTRIBUTE TO IDS SATISFACTION IN PATIENTS WITH TYPE 2 DIABETES
	Yang HK1, Hayes RP2, Boye KS2
	1University of Maryland Baltimore, Baltimore, MD, USA, 2Eli Lilly and Company, Indianapolis, IN, USA
PDB61	PREDICTORS OF INSULIN DELIVERY SYSTEM USE IN PATIENTS WITH TYPE 2 DIABETES
	Molife C, Hayes RP
	Eli Lilly and Company, Indianapolis, IN, USA

DIABETES/ENDOCRINE DISORDERSHealth Care Use & Policy Studies
PDB62	DETERMINANTS OF INSULIN INITIATION FOR PATIENTS WITH TYPE 2 DIABETES
	Gibson TB1, Song X2, Alemayehu B3, Wang S4, Mell A1, Forma F3
	1Thomson Healthcare, Ann Arbor, MI, USA, 2Thomson Healthcare, Shrewsbury, MA, USA, 3Novo Nordisk, Inc, Princeton, NJ, USA, 4Thomson Healthcare, Cambridge, MA, USA
PDB63	AN ECONOMIC EVALUATION OF A DIABETES DISEASE MANAGEMENT PROGRAM FOR ADULT MEDICAID CLIENTS IN THE STATE OF COLORADO, UNITED STATES
	Skrepnek GH1, Armstrong EP1, Brookler K2, Roper J2, Martin BE2, Karabatsos L2, Hunter C2
	1University of Arizona, Tucson, AZ, USA, 2Colorado Department of Health Care Policy and Financing, Denver, CO, USA
PDB64	PHYSICIAN PRACTICE SPECIALTY AND TYPES OF ANTI-DIABETIC TREATMENTS FOR PATIENTS WITH TYPE 2 DIABETES: ARE THEY ASSOCIATED?---A LARGE NATIONAL OBSERVATIONAL STUDY IN A MANAGED CARE SETTING
	Sun P
	Kailo Research Group, Indianapolis, IN, USA
PDB65	COMPARISON OF FOUR HEALTH STATE PREFERENCE MEASURES AMONG PATIENTS ENROLLED IN THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES TRIAL
	Raisch DW1, Sullivan MD2, Narayan KMV3, Goff Jr DC4, O'Connor PJ5, Aron DC6, Feeney P7
	1Department of Veterans Affairs Cooperative Studies Program, Albuquerque, NM, USA, 2University of Washington, Seattle, WA, USA, 3Emory University, Atlanta, GA, USA, 4Wake Forest University School of Medicine, Winston-Salem, NC, USA, 5HealthPartners Research Foundation, Bloomington, MN, USA, 6Professor of Medicine and Epidemiology and Biostatistics, Cleveland, OH, USA, 7Wake Forest University Health Sciences, Winston-Salem, NC, USA
PDB66	HEALTH CARE UTILISATION AND EXPENDITURES ASSOCIATED WITH TREATMENTS OF DIABETES MELLITUS WITHIN THE SLOVAK REPUBLIC
	Tesar T1, Foltan V1, Ilavska A2
	1Comenius University, Bratislava, Slovak Republic, 2Railway Hospital, Bratislava, Slovak Republic
PDB67	DESCRIPTIVE ANALYSIS OF BODY WEIGHT AND CLINICAL EFFECTIVENESS MEASURES ASSOCIATED WITH TYPE 2 DIABETES THERAPIES IN A PRIMARY CARE ELECTRONIC MEDICAL RECORD DATABASE
	Nelson RE1, McAdam-Marx C1, Misurski D2, Nielsen L3
	1University of Utah, Salt Lake City, UT, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 3Amylin Pharmaceuticals, Inc, San Diego, CA, USA
PDB68	AN ASSESSMENT OF THE IMPACT OF THE COVERAGE GAP UPON MEDICARE PART D BENEFICIARIES UTILIZING INSULIN
	Skrepnek GH1, Denarie MF2, Conner C3, Forma FM3
	1University of Arizona, Tucson, AZ, USA, 2IMS Health Inc, Plymouth Meeting, PA, USA, 3Novo Nordisk Inc, Princeton, NJ, USA
PDB69	COMPARISON OF HEALTH CARE UTILIZATION AND COSTS IN TYPE 2 DIABETES PATIENTS INITIATING ANALOG AND HUMAN INSULINS
	Margolis J1, Johnson BH2, Chu BC3, Forma F4, Alemayehu B4
	1Thomson Healthcare, Washington, DC, USA, 2Thomson Healthcare, Cambridge, MA, USA, 3Thomson Healthcare, Santa Barbara, CA, USA, 4Novo Nordisk, Inc, Princeton, NJ, USA
PDB70	IMPACT OF ANEMIA ON HOSPITALIZATION COSTS IN PATIENTS WITH DIABETES AND CHRONIC KIDNEY DISEASE
	Laliberte F1, Bookhart B2, Corral M2, Duh MS3, Bailey R2, Lefebvre P1
	1Groupe d'analyse, Ltee, Montreal, QC, Canada, 2Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ, USA, 3Analysis Group, Inc, Boston, MA, USA
PDB71	EVALUATION OF ECONOMIC OUTCOMES, ADHERENCE, AND GLYCEMIC CONTROL FOR DIABETIC PATIENTS IN A PHARMACIST-RUN MEDICATION MANAGEMENT PROGRAM
	Hanson KA1, Prasla K2, Godley PJ1, Tabor T1, Juan J1, Rascati KL3, Klein MS1
	1Scott and White Health System, Temple, TX, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3The University of Texas at Austin, Austin, TX, USA
PDB72	THE NEED FOR EARLIER INSULIN INITIATION AND INTENSIFICATION AMONG PATIENTS WITH TYPE 2 DIABETES: EVIDENCE FROM HEALTH CLAIMS AND LABORATORY DATABASE.
	Sarpong EM1, Durden ED2
	1Eli Lilly and Company, Indinapolis, IN, USA, 2Thomson Medstat, Cambridge, MA, USA
PDB73	NON-INJECTABLE INSULIN – TO PAY OR NOT TO PAY?
	Piwko C1, Vicente C1, Markus GE2, Kappor A2, Seung SJ3, Mittmann N3
	1PIVINA Consulting Inc, Thornhill, ON, Canada, 2Generex Biotechnology Corp, Toronto, ON, Canada, 3HOPE Research Centre, Toronto, ON, Canada
PDB74	WITHDRAWN

PDB75	PRESCRIBING PATTERN AND PREDICTORS ASSOCIATED WITH THE USE OF HYPOGLYCAEMIC DRUGS: A CROSS-SECTIONAL STUDY IN ITALIAN GENERAL PRACTICE
	Alacqua M1, Mazzaglia G2, Medea G3, Innocenti F2, Mantovani LG4, Caputi AP1, Cricelli C5
	1University of Messina, Messina, Italy, 2Health Search – Italian College of General Practitioners, Florence, Italy, 3Italian College of General Practitioners, Florence, Italy, Florence, Italy, 4University of Naples, Federico II, Naples, Italy, 5Italian College of General Practioners, Florence, Italy
PDB76	PROFILING PHYSICIAN PRESCRIPTION BEHAVIOR WITH CANONICAL CORRESPONDENCE ANALYSIS
	Sun P
	Kailo Research Group, Indianapolis, IN, USA
PDB77	INVOLVEMENT OF LAY VOLUNTEERS IN TRAINING ON SELF-MANAGEMENT OF PATIENTS WITH DIABETES IN THE UNITED KINGDOM – COST IMPLICATIONS
	Wex J1, Baksi A2, Al-Mrayat M2, Hogan D2, Whittingstall E3, Wilson P4
	1PharmArchitecture Limited, London, England, UK, 2St. Mary's Hospital, Newport, Isle of Wight, UK, 3The Arun Baksi Centre for Diabetes and Endocrinology, Newport, Isle of Wight, UK, 4Vectasearch Clinic, Newport, Isle of Wight, UK
PDB78	MEASURING THE IMPACT OF AN EDUCATIONAL PROGRAM ON PHYSICIAN PRACTICE PATTERNS: EXPERTMD™ CV DIABETES
	Nemis-White J1, Beauchamp P2, Trasler T1, Lewanczuk R3
	1Merck Frosst Canada Ltd, Montreal, QC, Canada, 2University of Montreal, Montreal, QC, Canada, 3University of Alberta, Edmonton, AB, Canada
PDB79	USING DECISION ANALYTIC METHODS TO REDUCE COSTLY LABORATORY ERRORS: A TEST OF A PROBABILISTIC AUTOVERIFICATION SYSTEM
	Doctor JN1, Strylewicz G2
	1University of Southern California, Los Angeles, CA, USA, 2University of Washington, Seattle, WA, USA
PDB80	REDUCING COSTS AND IMPROVING OUTCOMES BY REDUCING MEDICAL ERRORS: A COMPARISON OF EXPERTS WITH PROBABLISTIC LABORATORY ERROR DETECTION IN A POPULATION OF PRE-DIABETICS
	Doctor JN1, Strylewicz G2

HEALTH CARE INTERVENTIONS Cost Studies
PHC1	A COST COMPARISON OF CARDIAC SURGERIES BY CHOICE OF FIBRIN SEALANT
	Narayan S1, Stemkowski S2, Conner TM3, Tucker M1, Shander A4
	1Baxter Healthcare Corporation, Westlake Village, CA, USA, 2Premier Inc, Charlotte, NC, USA, 3Outcomes Research Consulting, Austin, TX, USA, 4Englewood Hospital and Medical Center, Englewood, NJ, USA
PHC2	A COMPARISON OF COSTS ASSOCIATED WITH SPINAL SURGERIES BY CHOICE OF FIBRIN SEALANT
	Narayan S1, Stemkowski S2, Conner TM3, Tucker M1, Shander A4
	1Baxter Healthcare Corporation, Westlake Village, CA, USA, 2Premier Inc, Charlotte, NC, USA, 3Outcomes Research Consulting, Austin, TX, USA, 4Englewood Hospital and Medical Center, Englewood, NJ, USA
PHC3	COST-EFFECTIVENESS MODELING OF DENTAL IMPLANT 1ST LINE STRATEGY VERSUS BRIDGE
	Beresniak A1, Bouchard P2, Renouard F3, Bourgeois D4, Jeanneret MH5
	1Data Mining International, Geneva, Switzerland, 2University Denis Diderot, Paris, France, 3Centre d'Implantologie, Paris, France, 4University Lyon 1, Villeurbanne, France, 5University Paris-Descartes, Paris, French Guiana
PHC4	COST-EFFECTIVENESS ANALYSIS OF THROMBOPROPHYLACTIC STRATEGIES OVER 1 YEAR AFTER TOTAL HIP REPLACEMENT IN VETERAN PATIENTS
	Raisch DW1, Campbell HM1, Khan N2, Taylor Z1, Becker T1
	1Department of Veterans Affairs Cooperative Studies Program, Albuquerque, NM, USA, 2University of New Mexico, Albuquerque, NM, USA
PHC5	COST-EFFECTIVENESS ANALYSIS OF THROMBOPROPHYLACTIC STRATEGIES OVER ONE YEAR AFTER TOTAL KNEE REPLACEMENT IN VETERAN PATIENTS
	Campbell HM1, Raisch DW1, Taylor Z1, Khan N2, Becker T3
	1Department of Veterans Affairs Cooperative Studies Program, Albuquerque, NM, USA, 2University of New Mexico, Albuquerque, NM, USA, 3Department of Veteran Affairs Cooperative Studies Program, Albuquerque, NM, USA
PHC6	COST-EFFECTIVENESS COMPARISON OF TENSION-FREE MESH REPAIR VS. TENSION SUTURE REPAIR METHODS OF INGUINAL HERNIA IN HUNGARY
	Plisko R1, Metz L2, Dziewiatka M1
	1HTA Consulting, Krakow, Poland, 2Johnson & Johnson, Ethicon, Dilbeek, Belgium
PHC7	COST-EFFECTIVENESS COMPARISON OF TENSION-FREE MESH REPAIR VS. TENSION SUTURE REPAIR METHODS OF INGUINAL HERNIA IN POLAND
	Plisko R1, Metz L2, Dziewiatka M1
	1HTA Consulting, Krakow, Poland, 2Johnson & Johnson, Ethicon, Dilbeek, Belgium
PHC8	COST-EFFECTIVENESS COMPARISON OF TENSION-FREE MESH REPAIR VS. TENSION SUTURE REPAIR METHODS OF INGUINAL HERNIA IN SLOVAKIA
	Plisko R1, Metz L2, Dziewiatka M1
	1HTA Consulting, Krakow, Poland, 2Johnson & Johnson, Ethicon, Dilbeek, Belgium
PHC9	THE POTENTIAL SAVINGS IN OPERATING ROOM TIME ASSOCIATED WITH THE USE OF SUGAMMADEX TO REVERSE SELECTED NEUROMUSCULAR BLOCKING AGENTS: FINDINGS FROM A HOSPITAL EFFICIENCY MODEL
	Zhang B1, Menzin J1, Tran MH2, Neumann PJ3, Friedman M1, Sussman M1, Hepner D4
	1Boston Health Economics, Inc, Waltham, MA, USA, 2Organon International, a part of Schering-Plough Corporation, Roseland, NJ, USA, 3Tufts-New England Medical Center, Boston, MA, USA, 4Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
PHC10	AN ASSESSMENT OF HOSPITAL COSTS AND REIMBURSEMENT AMONG TOTAL HIP OR KNEE ARTHROPLASTY PATIENTS IN THE UNITED STATES THAT EXPERIENCE VENOUS THROMBOEMBOLISM
	Song X1, Sander S2, Huse D1, Harris K2, Amin AN3
	1Thomson Healthcare Inc, Cambridge, MA, USA, 2Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA, 3University of California, Irvine, Irvine, CA, USA
HEALTH CARE INTERVENTIONS Patient-Reported Outcomes
PHC11	A SYSTEMATIC REVIEW OF STUDIES ON QUALITY OF LIFE IN ANIMALS
	Poulsen Nautrup B1, Van Vlaenderen I2, Poulsen Nautrup C3
	1EAH Consulting, Juelich, Northrhine Westf, Germany, 2IMS Health, Brussels, Belgium, 3Ludwig-Maximilians-University, Munich, Germany
HEALTH CARE INTERVENTIONS Health Care Use & Policy Studies
PHC12	STARR PROCEDURE FOR OBSTRUCTED DEFAECATION SYNDROME (ODS): 12-MONTH FOLLOW-UP
	Ribaric G1, Jayne DR2, Stuto A3, Schwandner O4, Morlotti L1
	1Ethicon Endo Surgery, Norderstedt, Germany, 2St. James's University Hospital, Leeds, UK, 3Ospedale Santa Maria degli Angeli, Pordenone, Italy, 4Caritas-Krankenhaus St. Josef, Regensburg, Germany

INDIVIDUAL’S HEALTH Clinical Outcomes Studies
PIH1	PREVENTION OF FALLS AND FALL-RELATED INJURIES IN THE COMMUNITY-DWELLING ELDERLY: A REVIEW
	Gomes T1, Chandra KM2
	1Ministry of Health and Long-Term Care, Toronto, ON, Canada, 2Program for Assessment of Technology in Health, Hamilton, ON, Canada
PIH2	CONTRACEPTIVE FAILURE RATES AMONG MEDICAID AND NON-MEDICAID ENROLLEES
	Bradford WD1, McCullough JS2, Chang J3, Costales AC3, Gricar JA4
	1Medical University of South Carolina, Charleston, SC, USA, 2University of Minnesota, Minneapolis, MN, USA, 3Bayer HealthCare Pharmaceuticals, Inc, Wayne, NJ, USA, 4Independent Health Care Consultant, New York, NY, USA
PIH3	HOSPITALIZATIONS AND MORTALITY ASSOCIATED WITH INCIDENT POTENTIALLY INAPPROPRIATE MEDICATIONS USE AMONG ELDERLY INDIANA MEDICAID BENEFICIARIES RESIDING IN NURSING HOMES
	Dedhiya S1, Craig B2, Sands L2, Thomas III J2
	1Purdue University, West Lafayette, IN, USA, 2Purdue University, Regenstrief Center for Healthcare Engineering, Center for Health Outcomes Research and Policy, West Lafayette, IN, USA
PIH4	COMPARISON OF MEN AGE 21 YEARS AND OLDER WITH AND WITHOUT ERECTILE DYSFUNCTION ON CONCOMITANT PRESCRIPTION DRUG, COMORBID CONDITIONS, SMOKING STATUS AND BMI
	Roper MA1, Biskupiak J2, Alder SC1, Oderda GM1
	1University of Utah, Salt Lake City, UT, USA, 2The University of Utah College of Pharmacy, Salt Lake City, UT, USA
PIH5	THE EFFECT OF INJURY SEVERITY ON THE INCIDENCE AND RESOURCE UTILIZATION-RELATED OUTCOMES OF DEEP VEIN THROMBOSIS AMONG PEDIATRIC TRAUMA ADMISSIONS IN THE UNITED STATES
	Candrilli SD1, Balkrishnan R1, O'Brien S2
	1The Ohio State University, Columbus, OH, USA, 2The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA
INDIVIDUAL’S HEALTHCost Studies
PIH6	ECONOMIC ASSESSMENT OF SILDAFENIL FOR THE MANAGEMENT OF PATIENTS WITH ERECTILE DYSFUNCTION (ED) SECONDARY TO DIABETES MELLITUS TYPE 2 (DM2) AND HYPERTENSION IN MEXICO
	Arreola-Ornelas H1, Dorantes-Aguilar J1, García-Mollinedo MDL2, Rosado-Buzzo AA2, Mould-Quevedo J3, Davila-Loaiza G3
	1Fundación Mexicana para la Salud, Funsalud, Mexico City, Mexico, 2Links & Links S.A. de C. V, Mexico City, Mexico, 3Pfizer Mexico, Mexico City, Mexico
PIH7	BURDEN OF ILLNESS OF HYPERTENSION AMONG WOMEN USING MENOPAUSAL HORMONE THERAPY
	Pelletier E1, Gricar JA2, Chang J3, Nahum GG3, Mittapally R1
	1IMS Health, Watertown, MA, USA, 2Independent HealthCare Consultant, New York, NY, USA, 3Bayer HealthCare Pharmaceuticals, Wayne, NJ, USA
PIH8	COST-EFFECTIVENESS OF ORAL AND TRANSDERMAL CONTRACEPTIVES
	Zaliska O, Pushak K
	Lviv National Medical University Named Danylo Galitsky, Lviv, Ukraine
PIH9	COST-EFFECTIVENESS ANALYSIS OF CONTRACEPTIVES AVAILABLE IN UNITED STATES
	Trussell J1, Lalla AM2, Doan QV2, Reyes E2, Pinto L2, Gricar JA3
	1Princeton University, Princeton, NJ, USA, 2Cerner LifeSciences, Cerner Corporation, Beverly Hills, CA, USA, 3Independent HealthCare Consultant, New York, NY, USA
PIH10	THE COST-EFFECTIVENESS OF ROUTINE SCREENING FOR VASA PREVIA AT 18-20 WEEKS GESTATION IN ONTARIO
	Cipriano LE1, Barth WH1, Zaric GS2
	1Massachusetts General Hospital, Boston, MA, USA, 2University of Western Ontario, London, ON, Canada
PIH11	IMPACT OF THE RISK SCORING MODEL ON THE COST-EFFECTIVENESS OF PALIVIZUMAB FOR RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS IN PREMATURE INFANTS WITH A GESTATIONAL AGE OF 32-35 WEEKS IN CANADA
	Lanctôt KL1, Paes B2, Francis PL1, Chiu A3, Hui C4, Oh PI5
	1Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 2McMaster University, Hamilton, ON, Canada, 3University of Manitoba, Winnipeg, Manitoba, Canada, 4Children's Hospital of Eastern Ontario, Ottawa, ON, Canada, 5Toronto Rehabilitation Institute, North York, ON, Canada
PIH12	WITHDRAWN


PIH13	A CONCEPTUAL FRAMEWORK TOWARD A MODIFIED REFERENCE CASE FOR DEVELOPING COUNTRIES: INCORPORATING DONOR FUNDING FLOWS IN COST-EFFECTIVENESS ANALYSIS
	Gauvreau CL
	University of Toronto, Toronto, ON, Canada
PIH14	ECONOMIC EVALUATION OF ATOSIBAN VERSUS BETA-MIMETICS IN THE TREATMENT OF PRETERM LABOUR IN GERMANY
	Wex J1, Connolly MP2, Schneider D2
	1PharmArchitecture Limited, London, United Kingdom, 2Ferring International Center, Saint-Prex, Switzerland
PIH15	STUDENT PHARMACIST INTERVENTIONS LEAD TO COST MINIMIZATION OF MEDICARE PART D PRESCRIPTION DRUG PLAN COSTS
	Lipton HL1, Patel RA2, Smith AR1, Cutler TW1, Stebbins MR1
	1University of California, San Francisco, San Francisco, CA, USA, 2University of the Pacific, Stockton, CA, USA
PIH16	THE DIRECT COSTS OF INJURIOUS FALLS IN SENIORS
	Woolcott JC1, Khan K1, Davis JC1, Buchanan J2, Abu-Laban RB2, Marra CA1
	1University of British Columbia, Vancouver, BC, Canada, 2Vancouver General Hospital, Vancouver, BC, Canada
PIH17	COST-EFFECTIVENESS OF MAGNETIC RESONANCE-GUIDED FOCUSED ULTRASOUND SURGERY FOR TREATMENT OF UTERINE FIBROIDS
	Zowall H1, Cairns JA2, Brewer C3, Lamping DL4, Gedroyc WM5, Regan L5
	1McGill University, Montreal, QC, Canada, 2London School of Hygiene and Tropical Medicine, London, UK, 3Zowall Consulting, Westmount, QC, Canada, 4London School of Hygiene & Tropical Medicine, London, UK, 5St. Mary’s Hospital and Imperial College School of Medicine, London, UK
INDIVIDUAL’S HEALTH Patient-Reported Outcomes
PIH18	ASSESSING THE ASSOCIATION BETWEEN SCORE DIFFERENCES ON THE PREMENSTRUAL SYMPTOMS IMPACT SURVEY (PMSIS) AND HEALTH-RELATED QUALITY OF LIFE
	Yang M1, Chang J2, Gricar JA3
	1QualityMetric Health Outcomes Solutions, Lincoln, RI, USA, 2Bayer HealthCare Pharmaceuticals, Inc, Wayne, NJ, USA, 3Independent HealthCare Consultant, New York, NY, USA
PIH19	PREDICTING RISK OF WORK LOSS ASSOCIATED WITH PREMENSTRUAL SYNDROME (PMS) AND PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING PHYSICAL COMPONENT SUMMARY (PCS) SCORE
	Yang M1, Chang J2, Gricar JA3
	1QualityMetric Health Outcomes Solutions, Lincoln, RI, USA, 2Bayer HealthCare Pharmaceuticals, Inc, Wayne, NJ, USA, 3Independent HealthCare Consultant, New York, NY, USA
PIH20	PREDICTING RISK OF WORK LOSS ASSOCIATED WITH PREMENSTRUAL SYNDROME AND PREMENSTRUAL DYSPHORIC DISORDER USING MENTAL COMPONENT SUMMARY (MCS) SCORE
	Yang M1, Chang J2, Gricar JA3
	1QualityMetric Health Outcomes Solutions, Lincoln, RI, USA, 2Bayer HealthCare Pharmaceuticals, Inc, Wayne, NJ, USA, 3Independent HealthCare Consultant, New York, NY, USA
PIH21	LITERATURE REVIEW OF DISCRETE CHOICE EXPERIMENTS TO ASSESS WOMEN'S PREFERENCES AND WILLINGNESS TO PAY FOR MATERNAL HEALTH SERVICES
	Hancock RL1, Ungar WJ2, Koren G1, Einarson A1, Goodstadt M3
	1Hospital for Sick Children, Toronto, ON, Canada, 2The Hospital for Sick Children, Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada
PIH22	CARESS: THE CANADIAN REGISTRY OF SYNAGIS®
	Lanctôt KL1, Mitchell I2, Paes B3, Reim EK1
	1Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 2University of Calgary, Calgary, AB, Canada, 3McMaster University, Hamilton, ON, Canada
PIH23	PATIENT SATISFACTION WITH ERECTILE DYSFUNCTION TREATMENT: SILDENAFIL VS. FOOD SUPPLEMENTS
	Skoupá J1, Zamecnik L2, Cerna V1, Hájek P3, Kovár P3
	1Pharma Projects, Prague, Czech Republic, 21st Medical Faculty Charles University, Prague, Czech Republic, 3Pfizer, Praha 5, Czech Republic
INDIVIDUAL’S HEALTH Health Care Use & Policy Studies
PIH24	AN ANALYSIS OF POTENTIALLY INAPPROPRIATE MEDICATION USE IN THE DUALLY ELIGIBILE MEDICARE AND MEDICAID POPULATION USING THE NEW 2003 BEERS DRUG UPDATE
	Blackwell SA, Ciborowski G, Baugh DK, Montgomery MA
	Centers for Medicare & Medicaid Services, Baltimore, MD, USA
PIH25	VARIATIONS IN ANTIPSYCHOTIC THERAPY AND SHORT-TERM MORTALITY ACROSS LONG-TERM CARE HOMES
	Bronskill SE1, Rochon PA1, Gill SS2, Herrmann N3, Hillmer MP1, Bell C4, Anderson GM1, Stukel TA1
	1Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, 2Queen's University, Kingston, ON, Canada, 3Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 4St. Michael's Hospital, Toronto, ON, Canada
PIH26	WITHDRAWN


PIH27	GENERIC SUBSTITUTION OF WARFARIN AMONG THE ELDERLY: AN EXAMINATION OF HOSPITAL AND EMERGENCY ROOM USE
	Banahan III BF, Wilkin NE, Mendonca CM
	University of Mississippi, University, MS, USA
PIH28	AN EXAMINATION OF LOW AVERAGE DOSE AS A QUALITY MEASURE OF THE NEED FOR ANTICOAGULATION MANAGEMENT AMONG THE ELDERLY
	Banahan III BF, Wilkin NE, Mendonca CM
	University of Mississippi, University, MS, USA
PIH29	ESTIMATION OF TYPE AND NUMBER OF MEDICATION ERRORS IN LONG-TERM CARE
	Kohaupt I, Lungen M, Lauterbach KW, Gerber A
	University of Cologne, Koeln, Germany
PIH30	PRIVATE HEALTH INSURANCE VS. MEDICAID COVERAGE: DISPARITIES IN PROCESS OF CARE MEASURES
	Marehbian J1, Chen JY2, Legorreta AP3
	1Health Benchmarks, Inc, Woodland Hills, CA, USA, 2Health Benchmarks Inc, Woodland Hills, CA, USA, 3UCLA School of Public Health, Los Angeles, CA, USA

MUSCULAR-SKELETAL DISORDERS Clinical Outcomes Studies
PMS1	EFFECT OF BISPHOSPHONATES ON FRACTURES IN POSTMEOPAUSAL WOMEN: A SYSTEMATIC LITERATURE REVIEW
	Reddy P1, Fiumara K2, Yeh YC1, Clapp M3, Churchill W2
	1Partners Healthcare, Charlestown, MA, USA, 2Brigham and Women's Hospital, Boston, MA, USA, 3Massachusetts General Hospital, Boston, MA, USA
PMS2	COMPARATIVE EFFICACY OF BIOLOGICAL TREATMENTS IN PATIENTS WITH PSORIATIC ARTHRITIS; SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS
	Brodszky V1, Karpati K1, Pentek M2, Boncz I3, Sebestyén A4, Gulacsi L1
	1Corvinus University of Budapest, Budapest, Hungary, 2Flor Ferenc County Hospital, Kistarcsa, Hungary, 3University of Pécs, Pécs, Hungary, 4National Health Insurance Fund Administration, Budapest, Hungary
PMS3	EFFICACY OF COX-2 SELECTIVE NSAIDS, NON-SELECTIVE NSAIDS, AND ACETAMINOPHEN IN OSTEOARTHRITIS: A BAYESIAN MIXED TREATMENT COMPARISON
	Jansen JP1, Gaugris S2, Stam W3
	1Mapi Values, Boston, MA, USA, 2Merck & Co., Inc, Whitehouse Station, NJ, USA, 3Mapi Values, Houten, Netherlands
PMS4	THE EFFECT OF HOSPITAL VOLUME ON 30 DAYS MORTALITY FOLLOWING HIP FRACTURE
	Sebestyén A1, Boncz I2, Nyárády J2, Kriszbacher I2, Gulácsi L3, Sándor J2
	1National Health Insurance Fund Administration, Budapest, Hungary, 2University of Pécs, Pécs, Hungary, 3Corvinus University of Budapest, Budapest, Hungary
PMS5	WHAT HAPPENED TO VIOXX USERS?
	Huse D1, Marder WD1, Hansen LG2
	1Thomson Healthcare, Cambridge, MA, USA, 2Thomson Healthcare, Northwood, NH, USA
MUSCULAR-SKELETAL DISORDERS Cost Studies
PMS6	BUDGET IMPACT ANALYSIS OF ABATACEPT INCLUSION FOR MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN THE BRAZILIAN PUBLIC SYSTEM
	Alves MR1, Carvalho Jr F1, Litalien G2
	1Bristol-Myers Squibb Pharmaceutical, Sao Paulo, Brazil, 2Bristol-Myers Squibb Pharmaceutical, Wallingford, CT, USA
PMS7	TREATMENT OF DISPLACED FEMORAL NECK FRACTURES IN THE ELDERLY: A COST BENEFIT ANALYSIS
	Alolabi B1, Bajammal S2, Shirali J2, Karanicolas PJ1, Gafni A2, Bhandari M2
	1University of Western Ontario, London, ON, Canada, 2McMaster University, Hamilton, ON, Canada
PMS8	HEALTH ECONOMICS MODEL FOR TOTAL HIP ARTHROPLASTY: COST SAVINGS ACHIEVED BY NEWER TECHNOLOGY
	Peoples S1, Rizzo J2, Kotlarz HJ1
	1DePuy Orthopaedics, Warsaw, IN, USA, 2Stony Brook University, Stony Brook, NY, USA
PMS9	COST-EFFECTIVENESS OF ABATACEPT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA) AND INADEQUATE RESPONSE TO METHOTREXATE (MTX) OR TUMOR NECROSIS FACTOR-ALPHA INHIBITORS (ANTI-TNFS): A CANADIAN PERSPECTIVE
	Maier-Moldovan M1, Yuan Y2, Maclean R3, L'Italien GJ4
	1Bristol-Myers Squibb, Saint-Laurent, QC, Canada, 2Bristol Myers Squibb, Princeton, NJ, USA, 3Bristol-Myers Squibb Pharmaceuticals, Lawrenceville, NJ, USA, 4Bristol Myers Squibb, Wallingford, CT, USA
PMS10	THE COST-EFFECTIVENESS OF ABATACEPT VERSUS RITUXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: A PERSPECTIVE OF THE CANADIAN PUBLICLY FUNDED HEALTH CARE SYSTEM
	Yuan Y1, Maier-Moldovan M2, Maclean R3, L'Italien GJ4
	1Bristol Myers Squibb, Princeton, NJ, USA, 2Bristol-Myers Squibb, Saint-Laurent, QC, Canada, 3Bristol-Myers Squibb Pharmaceuticals, Lawrenceville, NJ, USA, 4Bristol Myers Squibb, Wallingford, CT, USA
PMS11	COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB FOR RHEUMATOID ARTHRITIS IN TAIWAN
	Lou SF1, Chen DY2, Cheng TT3, Huang CM4, Lin HY5, Su CC6, Tsai WC7, Tseng JC8, Wei CC9, Yang L10, Hazard S11, Chang DM12
	1Chang Gung Memorial Hospital, Linkou, Taiwan, 2Taichung Veterans General Hospital, Taichung, Taiwan, 3Chang Gung Memorial Hospital, Koushung, Taiwan, 4China Medical University Hospital, Taichung, Taiwan, 5Taipei Veterans General Hospital, Taipei, Taiwan, 6Changhua Christian Hospital, Changhua, Taiwan, 7Kaoshiung Medical University Hospital, Kaoshiung, Taiwan, 8Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, 9Chung Shan Medical University Hospital, Taichung, Taiwan, 10Roche Products Ltd, Taipei, Taiwan, 11F. Hoffmann-La Roche AG, Basel, Switzerland, 12Tri-service General Hospital, Taipei, Taiwan
PMS12	COST-EFFECTIVENESS ANALYSIS OF ZOLEDRONIC ACID VERSUS RISEDRONATE FOR THE PREVENTION OF OSTEOPOROTIC HIP FRACTURE IN THE PRIVATE HEALTH CARE SYSTEM IN BRAZIL
	Araujo D1, Bahia L2, Souza CPR3, Benitez R3, Fernandes RA3, Bueno RLP4, Navarro J5, Matsui M6
	1State University of Rio de Janeiro, Rio de Janeiro, Brazil, 2Brazilian Society of Diabetes, Rio de Janeiro, Brazil, 3MedInsight, Rio de Janeiro, Brazil, 4FEI, São Paulo, Brazil, 5Novartis Farmacêutica S.A, São Paulo, Brazil, 6Bausch & Lomb, São Paulo, Brazil
PMS13	COST EFFECTIVENESS OF BIOLOGICS FOR RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW
	Pham B1, McMartin K2, Bornstein M3, Machado M4, Bombardier C5, Krahn MD6, Levin L3
	1Toronto Health Economics and Technology Assessment Collaborative, Toronto, ON, Canada, 2Ontario Ministry of Health and Longterm Care, Toronto, ON, Canada, 3Ontario Ministry of Health and LongTerm Care, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada, 5Toronto General Hospital, Toronto, ON, Canada, 6University Health Network, Toronto, ON, Canada
PMS14	A COST-EFFECTIVENESS ANALYSIS OF BIOLOGICAL AGENTS FOR PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS FOLLOWING INADEQAUTE RESPONSE TO METHOTREXATE
	Gandhi PK1, Spooner JJ2, Viraparia P1, Kauf TL1
	1University of Florida, Gainesville, FL, USA, 2Advanced Concepts Institute, Philadelphia, PA, USA
PMS15	COST-EFFECTIVENESS OF THE TREATMENT FOR EARLY RHEUMATOID ARTHRITIS IN MEXICO: INFLIXIMAB VS. ADALIMUMAB
	Muciño E1, Rivas R2, Zapata L2
	1Instituto de Salud Publica, Cuernavaca, Morelos, Mexico, 2Guia Mark, México, DF, Mexico
PMS16	ECONOMIC EVALUATION OF MONTHLY IBANDRONATE VS WEEKLY ALENDRONATE TO PREVENT OSTEOPOROTIC HIP FRACTURES IN MEXICAN WOMEN AGED FIFTY AND OLDER
	Gasca-Pineda R, Rivera-Hurtado R
	Roche, Mexico City, Mexico D.F, Mexico
PMS17	LONGITUDINAL ESTIMATES AND COST-EFFECTIVENESS ANALYSIS OF ANTI-RESORPTIVE AGENTS FOR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND FRACTURES BASED ON US NATIONAL SURVEYS
	Yeh JY1, Lawson K2, Novak S3, Rascati KL2, Barner JC2, Johnsrud M2
	1Cleveland Clinic, Cleveland, OH, USA, 2The University of Texas at Austin, Austin, TX, USA, 3The JeSTARx Group, Austin, TX, USA
PMS18	COST-EFFECTIVENESS OF ABATACEPT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE IN BRAZIL
	Alves MR1, Carvalho Jr F1, Litalien G2
	1Bristol-Myers Squibb, Sao Paulo, Brazil, 2Bristol Myers Squibb Pharmaceutical, Wallingford, CT, USA
PMS19	COST MINIMIZATION AND BUDGET IMPACT ANALYSIS OF RITUXIMAB VERSUS INFLIXIMAB, ADALIMUMAB, ETANERCEPT AND ABATACEPT IN RHEUMATOID ARTHRITIS FROM A PAYER PERSPECTIVE IN BRAZIL
	Saggia MG, Santos EA, Nasciben V
	Roche Brazil, Sao Paulo, SP, Brazil
PMS20	THE ECONOMIC CONSEQUENCES OF RHEUMATOID ARTHRITIS: AN ANALYSIS OF THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS)
	Simons WR1, Rosenblatt LC2, Trivedi DN2
	1Global Health Economics & Outcomes Research, Inc, Summit, NJ, USA, 2Bristol-Myers Squibb Company, Plainsboro, NJ, USA
PMS21	THE RELATIONSHIP BETWEEN COST OF ILLNESS AND DISEASE SEVERITY IN RHEUMATOID ARTHRITIS: RESULTS OF A SYSTEMATIC REVIEW
	Richard L1, Brown M1, Blackwell AD2
	1UCB Celltech, Slough, Berkshire, UK, 2Global Health Outcomes UCB, Smyrna, GA, USA
PMS22	ECONOMIC IMPACT OF ALLOPURINOL HYPERSENSITIVITY SYNDROME
	D'Souza AO1, Fuldeore MJ2, Khanna D3, Meissner BL1, Dabbous OH2
	1Xcenda, Palm Harbor, FL, USA, 2TAP Pharmaceutical Products Inc, Lakeforest, IL, USA, 3UCLA, Los Angeles, CA, USA
PMS23	MODELLING OF BURDEN OF FEMORAL NECK FRACTURE IN 2007 FROM PURCHASER'S POINT OF VIEW
	Sebestyén A1, Boncz I2, Kriszbacher I2, Betlehem J2, Tóth F2, Péntek M3, Gulácsi L4, Nyárády J2, Brodszky V4
	1National Health Insurance Fund Administration, Budapest, Hungary, 2University of Pécs, Pécs, Hungary, 3Flor Ferenc County Hospital, Kistarcsa, Hungary, 4Corvinus University of Budapest, Budapest, Hungary
PMS24	RESOURCE UTILIZATION AMONG INPATIENTS WITH RHEUMATOID ARTHRITIS – AN ANALYSIS OF 2004 HEALTH CARE COST AND UTILIZATION PROJECT DATA
	Parekh HH1, Kamal KM2, Smith MJ3, Skomo ML2
	1i3 Innovus, Medford, MA, USA, 2Duquesne University, Pittsburgh, PA, USA, 3West Virginia University, Morgantown, WV, USA
PMS25	ASSOCIATION BETWEEN OUT-OF-POCKET EXPENSES AND CLINICAL OUTCOMES, AND QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS
	Tang B1, Rahman MI1, Annunziata K2, Thompson H1, Naim A1, Freedman D2
	1Centocor, Inc, Horsham, PA, USA, 2Consumer Health Sciences, Princeton, NJ, USA
PMS26	TRENDS IN HOSPITALIZATIONS AMONG INPATIENTS WITH RHEUMATOID ARTHRITIS – AN ANALYSIS OF 2002-2004 HEALTH CARE COST AND UTILIZATION PROJECT DATA
	Parekh HH1, Kamal KM2, Skomo ML2, Smith MJ3
	1i3 Innovus, Medford, MA, USA, 2Duquesne University, Pittsburgh, PA, USA, 3West Virginia University, Morgantown, WV, USA
PMS27	DOES THE FUNDING SOURCE INFLUENCE THE RESULTS IN ECONOMIC EVALUATIONS? A CASE- STUDY IN BISPHOSPHONATES FOR THE TREATMENT OF OSTEOPOROSIS
	Fleurence RL1, Spackman E2, Hollenbeak C3
	1United BioSource Corporation Health Analytics Group, Bethesda, MD, USA, 2United BioSource Corporation Health Analytics Group, Seattle, WA, USA, 3Penn State College of Medicine, Hershey, PA, USA
PMS28	REAL WORLD COSTS AND DOSING PATTERNS OF ABATACEPT AND INFLIXIMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
	Trivedi DN, Kreilick C, Rosenblatt LC
	Bristol-Myers Squibb Company, Plainsboro, NJ, USA
PMS29	BAYESIAN COST-EFFECTIVENESS ANALYSIS OF TREATMENT OF ANKYLOSING SPONDYLITIS
	Jansen JP1, Gaugris S2, Stam W3
	1Mapi Values, Boston, MA, USA, 2Merck & Co., Inc, Whitehouse Station, NJ, USA, 3Mapi Values, Houten, Netherlands
PMS30	EFFECTS OF 12-HOUR, EXTENDED-RELEASE HYDROCODONE/ACETAMINOPHEN ON PAIN-RELATED WORK PRODUCTIVITY: A SUBANALYSIS FROM A 56-WEEK OPEN-LABEL STUDY
	Webster D1, Herrington D2, Corser B3, Rapoport R4, Dikranian AH5, Thomas JW6, Vo PG6, Marx SE6, Best AE6, Jain R6
	1Team Research of Central Texas, Killeen, TX, USA, 2Benchmark Research, San Angelo, TX, USA, 3Community Research, Cincinnati, OH, USA, 4Phase III Clinical Research - Truesdale Clinical, Fall River, MA, USA, 5San Diego Arthritis Medical Clinic, San Diego, CA, USA, 6Abbott Laboratories, Abbott Park, IL, USA
MUSCULAR-SKELETAL DISORDERS Patient-Reported Outcomes
PMS31	TWO-YEAR LONGITUDINAL STUDY OF PERSISTENCE TO ANTI-TUMOR NECROSIS FACTOR TREATMENT AMONG RHEUMATOID ARTHRITIS PATIENTS
	Tang B1, Rahman MI1, Naim A1, Changolkar A2
	1Centocor, Inc, Horsham, PA, USA, 2SOAL PharmaTech Solutions, LLC, Philadelphia, PA, USA
PMS32	RELATIONSHIP BETWEEN PATIENTS' COMPLIANCE TO RA SPECIALTY MEDICATIONS AND TOTAL HEALTH CARE COSTS
	Jiang JZ1, Khandelwal NG1, Moyer S2, Merten S1, Lee KY1
	1Walgreens Health Services, Deerfield, IL, USA, 2Walgreens Health Services, Phoenix, AZ, USA
PMS33	RELATIONSHIP BETWEEN PATIENTS' COMPLIANCE TO MS SPECIALTY MEDICATIONS AND TOTAL HEALTH CARE COSTS
	Khandelwal NG1, Jiang JZ1, Moyer S2, Merten S1, Lee KY1
	1Walgreens Health Services, Deerfield, IL, USA, 2Walgreens Health Services, Phoenix, AZ, USA
PMS34	A TWO-YEAR EVALUATION OF HEALTH OUTCOMES IN OSTEOARTHRITIS PATIENTS AFTER TOTAL KNEE REPLACEMENT
	Xie F1, Luo N2, Lo NN3, Goeree RA1, Tarride JE1, O'Reilly D1, Lee HP2
	1McMaster University, Hamilton, ON, Canada, 2National University of Singapore, Singapore, Singapore, 3Singapore General Hospital, Singapore, Singapore
PMS35	QUALITY OF LIFE AMONG OUTPATIENTS WITH RHEUMATOID ARTHRITIS IN A REAL-LIFE SETTING IN GERMANY
	Deeg M1, Langer HE2, Langer A3, Wasem J4
	1Wyeth Pharma GmbH, Münster, Germany, 2Rheumatologische Schwerpunktpraxis, Düsseldorf, Germany, 3RWTH Aachen, Aachen, Germany, 4University of Duisburg-Essen, Essen, Germany
PMS36	IMPROVEMENT IN SLEEP QUALITY FROM ABATACEPT TREATMENT IN RHEUMATOID ARTHRITIS PATIENTS
	Li T1, Wells G2, Tugwell P2
	1Bristol-Myers Squibb, Princeton, NJ, USA, 2University of Ottawa, Ottawa, ON, Canada
PMS37	ASSESSING THE VALIDITY AND RELIABILITY OF A SIMPLE ACTIVITY PARTICIPATION MEASURE FOR RHEUMATOID ARTHRITIS CLINICAL TRIALS
	Li T1, Wells G2, Tugwell P2
	1Bristol-Myers Squibb, Princeton, NJ, USA, 2University of Ottawa, Ottawa, ON, Canada
PMS38	ESTIMATING WORK PRODUCTIVITY: EFFECTS OF TRAMADOL EXTENDED-RELEASE TREATMENT
	Benson C1, Chang H2, Lerner D2, Rogers W2, Mody S1, Schein JR1
	1Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 2Tufts-New England Medical Center, Boston, MA, USA
PMS39	LOSS OF EMPLOYABLE LIFE-YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A PRELIMINARY ANALYSIS USING MARKOV MODEL
	Han C1, Tang B2, Parasuraman S3
	1Johnson & Johnson Pharmaceutical Services, LLC, Malvern, PA, USA, 2Centocor, Inc, Horsham, PA, USA, 3Johnson & Johnson Pharmaceutical Services, L.L.C, Malvern, PA, USA
PMS40	ORAL VS INJECTABLE TREATMENTS: PATIENT PREFERENCE IN BRAZILIAN PATIENTS
	Boscatti FHG
	Produtos Roche Químicos e Farmacêuticos S.A, São Paulo, SP, Brazil
PMS41	WITHDRAWN


PMS42	A COMPARISON OF PROVINCIAL PRESCRIPTION-ONLY PHARMACEUTICAL DATABASE WITH SELF-REPORTED USAGE OF ACETAMINOPHEN AND NSAIDS ACCORDING TO OSTEOARTHRITIS STAGE IN BRITISH COLUMBIA
	Sayre EC1, Rahman MM2, Aghajanian J2, Kang W3, Cibere J3, Anis AH3, Jordan JM4, Badley EM5, Kopec JA3
	1Arthritis Research Centre of Canada and Simon Fraser University, Vancouver, BC, Canada, 2Arthritis Research Centre of Canada, Vancouver, BC, Canada, 3University of British Columbia, Vancouver, BC, Canada, 4University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 5University of Toronto, Toronto, ON, Canada
PMS43	CHARACTERISTICS OF PHARMACEUTICS HAVING NO ALTERNATIVES
	Yim EY, Kim DW, Chang JH, Choi DW, Lim SH, Park SE, Yi SY
	Health Insurance Review & Assessment Service, Seoul, Seoul, South Korea
PMS44	PRESCRIPTION TREATMENT PATTERNS IN PATIENTS WITH CHRONIC OSTEOARTHRITIS PAIN
	Ng DB1, Mackowiak J2, Slaton T2, Mody S1, Benson C1
	1Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 2Center for Outcomes Research, Chapel Hill, NC, USA
PMS45	A TWO-YEAR LONGITUDINAL STUDY OF SWITCHING PATTERNS AMONG ANTI-TUMOR NECROSIS FACTORS IN THE TREATMENT OF RHEUMATOID ARTHRITIS
	Tang B1, Rahman MI1, Naim A1, Changolkar A2
	1Centocor, Inc, Horsham, PA, USA, 2SOAL PharmaTech Solutions, LLC, Philadelphia, PA, USA
PMS46	TREATMENTS FOR UPPER-LIMB POST-STROKE SPASTICITY: A CRITICAL EVALUATION
	Olvey EL1, Grizzle AJ1, Armstrong EP1, Shah MV2
	1University of Arizona, Tucson, AZ, USA, 2Allergan, Inc, Irvine, CA, USA

RESPIRATORY-RELATED DISORDERS Clinical Outcomes Studies
PRS1	COMPARISON OF THE EFFECTIVENESS OF ONE VERSUS TWO ANTIBIOTICS IN THE TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA (CAP). AN ANALISYS USING PROPENSITY SCORE.
	Espinoza MA1, Ruiz M1, Zunino E2, Martinez MA1, Luchsinger V1, Silva C1, Avendaño L1
	1Universidad de Chile, Santiago, Región Metropoli, Chile, 2Hospital Dr. Lucio Córdova, Santiago, Región Metropoli, Chile
PRS2	A MIXED TREATMENT COMPARISON META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS OF PHARMACOLOGIC TREATMENTS FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE
	Baker WL, Baker EL, Coleman CI
	Hartford Hospital, Hartford, CT, USA
PRS3	A VALIDATION STUDY ON USING MORTALITY RISK STRATIFICATION TOOL TO STRATIFY ECONOMIC RISK IN PATIENTS WITH ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (AECOPD)
	Tabak YP1, Sun X1, Johannes RS1, Gupta V1, Darin R1, Shorr AF2
	1Cardinal Health, Marlborough, MA, USA, 2Washington Hospital Center, Washington, DC, USA
PRS4	PROGNOSTIC FACTORS OF PATIENTS TRANSFERRED TO CHRONIC RESPIRATORY CARE WARD
	Hung MC1, Yan YH2, Lin MS3, Chen CR3, Wang JD4
	1National Taiwan University and National Taiwan University Hospital, Taipei, Taiwan, 2National Taiwan University and Chia-Yi Christian Hospital, Chiayi City, Taiwan, 3Chia-Yi Christian Hospital, Chiayi, Taiwan, 4National Taiwan University, Taipei, Taiwan
PRS5	IMPACT OF TOBACCO SMOKE EXPOSURE ON EXACERBATION FREQUENCY, SEVERITY, AND INHALER USE IN ASTHMATIC CHILDREN
	Everett BL, Hong SH
	University of Tennessee Health Science Center, Memphis, TN, USA
RESPIRATORY-RELATED DISORDERS Cost Studies
PRS6	A COST-EFFECTIVENESS MODEL FOR SMOKING CESSATION THERAPY USING VARENICLINE
	Viswanathan S, Neville W, Patel E, Raparla S, McGhan WF
	University of the Sciences in Philadelphia, Philadelphia, PA, USA
PRS7	COST-EFFECTIVENESS OF CICLESONIDE VERSUS FLUTICASONE IN THE TREATMENT OF PATIENTS WITH MILD, MODERATE, AND SEVERE ASTHMA
	Taylor DC1, DeLong K1, Nunes K1, Seal B2
	1i3 Innovus, Medford, MA, USA, 2Sanofi-Aventis, Bridgewater, NJ, USA
PRS8	HEALTH ECONOMICS OF ASTHMA: ASSESSING THE VALUE OF ASTHMA INTERVENTIONS
	Spackman DE, Campbell JD, Sullivan SD
	University of Washington, Seattle, WA, USA
PRS9	THE COST-EFFECTIVENESS OF TARGETED PRESCRIBING OF ANTIMICROBIALS IN CANADA FOR COMMUNITY-ACQUIRED PNEUMONIA IN AN ERA OF ANTIMICROBIAL RESISTANCE
	Moore L1, Martin M1, Quilici S1, Low DE2, Grossman R3, Kureishi A4, Kubin M5, Jaszewski B6, Rebeira M6
	1i3 Innovus, Uxbridge, Middlesex, UK, 2Mount Sinai Hospital, Toronto, ON, Canada, 3Credit Valley Hospital, Mississauga, ON, Canada, 4Bayer HealthCare, Singapore, Singapore, 5Bayer Healthcare AG, Wuppertal, Germany, 6Bayer Healthcare, Toronto, ON, Canada
PRS10	ECONOMIC AND CLINICAL OUTCOMES OF OMALIZUMAB USE FOR TREATING ASTHMA IN A MANAGED CARE POPULATION
	Prescott J
	The MCM Group, Marlton, NJ, USA
PRS11	LONG TERM COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS FOR SMOKING CESSATION IN CZECH REPUBLIC
	Skoupá J1, Dolezal T2, Hájek P3, Kovár P3
	1Pharma Projects, Prague, Czech Republic, 2Charles University in Prague, Prague 10, Czech Republic, 3Pfizer, Praha 5, Czech Republic
PRS12	INCREMENTAL COST-EFFECTIVENESS OF COMBINATION INHALER THERAPY IN MODERATE TO SEVERE COPD
	Oba Y
	University of Missouri-Columbia, Columbia, MO, USA
PRS13	PEDIATRIC ASTHMA: AN EMPLOYER PERSPECTIVE ON ANNUAL EMPLOYEE AND DEPENDENT COSTS FOR MEDICAL CARE AND PRESCRIPTION DRUGS
	Kleinman N1, Brook RA2, Ramachandran S3, Wagner S3
	1The HCMS Group, Cheyenne, WY, USA, 2The JeSTARx Group, Newfoundland, NJ, USA, 3AstraZeneca, Wilmington, DE, USA
PRS14	BENEFITS FROM IMPROVED ASTHMA CARE IN FINLAND 1987-2005 ASSESSED WITH ANALYSIS OF COMPREHENSIVE SOCIETAL COST AND BEHAVIOUR OF COST DRIVERS
	Reissell E1, Herse F1, Väänänen JJP1, Rinta S2, Bengtström M2, Tamminen N2, Parvinen PMT1
	1Nordic Healthcare Group, Helsinki, Finland, 2Pharma Industry Finland, Helsinki, Finland
PRS15	THE BURDEN OF NASAL CONGESTION IN THE UNITED STATES
	Stull D1, Ivanova JI2, Long G3, Birnbaum HG3, Crespi S4, Sandor DW5
	1United Biosource Corporation, Bethesda, MD, USA, 2Analysis Group, Inc, New York, NY, USA, 3Analysis Group, Inc, Boston, MA, USA, 4Schering-Plough Corp, Kenilworth, NJ, USA, 5Touro University College of Medicine, Hackensack, NJ, USA
PRS16	INCREMENTAL DIRECT MEDICAL EXPENDITURES ASSOCIATED WITH ADULT ASTHMA IN THE UNITED STATES
	Kamble S1, Bharmal M2
	1The University of North Carolina at Charlotte, Charlotte, NC, USA, 2Quintiles, Falls Church, VA, USA
PRS17	ECONOMIC OUTCOMES IN PATIENTS WITH CYSTIC FIBROSIS: A REVIEW OF THE LITERATURE
	Toy EL1, Weiner JR2, Sacco P3, Duh MS2
	1Analysis Group, Inc, Lakewood, CO, USA, 2Analysis Group, Inc, Boston, MA, USA, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
PRS18	COST-UTILITY ANALYSIS OF VARENICLINE, AN ORAL SMOKING CESSATION DRUG, IN JAPAN
	Igarashi A, Fukuda T, Tsutani K
	The University of Tokyo, Tokyo, Japan
PRS19	SMOKING-CESSATION THERAPY USING VARENICLINE - THE COST-UTILITY OF AN ADDITIONAL 12-WEEK COURSE OF VARENICLINE FOR THE MAINTENANCE OF SMOKING ABSTINENCE
	Bolin K1, Mörk AC2
	1Lund University, Lund, Sweden, 2Pfizer AB, Sollentuna, Sweden
PRS20	A LONG TERM COST-EFFECTIVENESS ANALYSIS MODEL FOR SMOKING CESSATION IN KOREA
	Bae JY1, Song HJ1, Joe KH2, Kim CH3, Song HR3, Ryu GC4, Kim DJ5, Lee EK1
	1Sook Myung Women's University, Seoul, South Korea, 2Department of Medicine, EulJi University, Seoul, South Korea, 3Family Medicine of Seoul Paik Hospital, seoul, South Korea, 4Korea Institute for Health and Social Affairs, seoul, South Korea, 5The catholic university of Korea, Holy family hospital, seoul, South Korea
RESPIRATORY-RELATED DISORDERS – Patient-Reported Outcomes
PRS21	MEDICATION ADHERENCE AND PERSISTENCE IN THE LAST YEAR OF LIFE IN COPD PATIENTS
	Jung E1, Pickard AS2, Salmon JW1, Bartle B3, Lee TA4
	1University of Illinois at Chicago, Chicago, IL, USA, 2College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA, 3Hines VA Hospital, Hines, IL, USA, 4Hines VA Hospital and Northwestern University, Chicago, IL, USA
PRS22	EFFECT OF PATIENTS' OUT-OF-POCKET COST ON ADHERENCE AND PERSISTENCE WITH OMALIZUMAB (XOLAIR) THERAPY FOR ALLERGIC ASTHMA
	Yu HT1, Solari P2, Wallace AE3, Sarawate C3, Hille J2, Curkendall S4
	1Cerner LifeSciences, Beverly Hills, CA, USA, 2Genentech, South San Francisco, CA, USA, 3HealthCore, Inc, Wilmington, DE, USA, 4Cerner LifeSciences, Vienna, WV, USA
PRS23	PARTICIPANTS' EXPERIENCE OF ASTHMA: RESULTS FROM A FOCUS GROUP STUDY
	Turner-Bowker DM1, Saris-Baglama RN1, DeRosa MA1, Paulsen CA2, Bransfield C2
	1QualityMetric Incorporated, Lincoln, RI, USA, 2American Institutes for Research, Concord, MA, USA
PRS24	CEILING EFFECTS AND DISCRIMINATION OF TREATMENT BENEFIT FOR PATIENTS WITH LOWER SYMPTOM SEVERITY: MEASUREMENT OF HEALTH UTILITIES IN ALLERGIC RHINITIS
	Stull D1, O'Quinn S1, Vestenbaek U2, Navaratnam P3
	1United BioSource Corporation, Bethesda, MD, USA, 2ALK-Abello, Copenhagen, Denmark, 3Informagenics, LLC, Worthington, OH, USA
PRS25	VALIDATION OF CLAIMS-BASED PERSISTENT ASTHMA SEVERITY CLASSIFICATION
	Yu AP1, Ivanova J2, Birnbaum H1, Hsieh M1, Seal B3, Emani S4, Rosiello R5, Colice G6
	1Analysis Group, Inc, Boston, MA, USA, 2Analysis Group, Inc, New York, NY, USA, 3Sanofi-Aventis, Bridgewater, NJ, USA, 4MGH Institute of Health Professions, Boston, MA, USA, 5Fallon Clinic, Worcester, MA, USA, 6Washington Hospital Center, Washington, DC, USA
PRS26	PREFERENCES FOR ONSET OF EFFECT OF COMBINATION MAINTENANCE MEDICATION AMONG ASTHMA PATIENTS
	Mohamed AF1, Johnson FR1, Hauber AB1, Meddis D2, Wagner S2
	1RTI Health Solutions, Research Triangle Park, NC, USA, 2AstraZeneca, Wilmington, DE, USA
PRS27	INTERPRETING CLINICAL TRIALS RESULTS FOR THE ONSET OF EFFECT QUESTIONNAIRE: METHODS AND RESULTS OF A DELPHI PANEL
	Harding G1, Leidy NK1, Kleinman L1, Meddis D2, Wagner S2
	1United BioSource Corporation, Bethesda, MD, USA, 2AstraZeneca, Wilmington, DE, USA
PRS28	ADHERENCE TO INHALED CORTICOSTEROID USE AND LOCAL ADVERSE EVENTS IN PERSISTENT ASTHMA
	Ivanova J1, Yu AP2, Birnbaum HG2, Hsieh M2, Seal B3, Van der Molen T4, Emani S5, Rosiello R6, Colice G7
	1Analysis Group, Inc, New York, NY, USA, 2Analysis Group, Inc, Boston, MA, USA, 3Sanofi-Aventis, Bridgewater, NJ, USA, 4University of Groningen, Groningen, Netherlands, 5MGH Institute of Health Professions, Boston, MA, USA, 6Fallon Clinic, Worcester, MA, USA, 7Washington Hospital Center, Washington, DC, USA
PRS29	PATIENT, CAREGIVER, AND PHYSICIAN PERCEPTIONS OF MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE: FINDINGS FROM QUALITATIVE RESEARCH
	Bentkover JD1, Beresford J2, Rogers B2, Schachtner AE1, Swensen A3, Dastani HB3
	1Innovative Health Solutions Corp, Brookline, MA, USA, 2National Emphysema/COPD Association, New York, NY, USA, 3Novartis Pharmaceuticals Corp, East Hanover, NJ, USA
PRS30	USE OF INTERACTIVE VOICE RESPONSE (IVR) TO COLLECT DAILY PATIENT DIARY DATA IN A CLINICAL TRIAL OF SEASONAL RHINITIS
	Tiplady B1, Campbell LM2
	1PRO Consulting, Twickenham, London, UK, 2Southbank Surgery, Kirkintilloch, Glasgow, UK
PRS31	IMPACT OF UNCONTROLLED PEDIATRIC ASTHMA ON CHILD AND CAREGIVER PRODUCTIVITY
	Dean BB1, Calimlim B1, Aguilar D1, Sacco P2, Maykut R2, Tinkelman D3
	1Cerner LifeSciences, Beverly Hills, CA, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3National Jewish Medical and Research Center, Denver, CO, USA
PRS32	IMPACT OF UNCONTROLLED ASTHMA ON PRODUCTIVITY AND ACTIVITY IMPAIRMENT
	Williams S1, Wagner S1, Kannan H2
	1AstraZeneca, Wilmington, DE, USA, 2Consumer Health Sciences, Princeton, NJ, USA
PRS33	TREATMENT SATISFACTION QUESTIONNAIRES IN ASTHMA AND OTHER CHRONIC DISEASES
	Staniek V1, Emery MP1, Marrel A2, Dias-Barbosa C2, Williams A3
	1Mapi Research Trust, Lyon, France, 2Mapi Values, Lyon, France, 3GlaxoSmithKline R&D, Uxbridge, UK
RESPIRATORY-RELATED DISORDERS Health Care Use & Policy Studies
PRS34	NICOTINE REPLACEMENT THERAPY AND THE MAINE TOBACCO HELPLINE: KNOWLEDGE, UTILIZATION PATTERNS, SHORT-TERM OUTCOMES, AND SATISFACTION AMONG SMOKERS
	Tworek C1, Haskins A2, Woods S3
	1West Virginia University, Morgantown, WV, USA, 2Center for Outcomes Research, Portland, ME, USA, 3Oregon Health & Science University, Portland, OR, USA
PRS35	A STATISTICAL LOOK AT COPD
	Cerrito PB, Augustus P
	University of Louisville, Louisville, KY, USA
PRS36	FACTORS ASSOCIATED WITH ANTIHISTAMINE PRESCRIBING IN ASTHMA IN THE UNITED STATES IN 2005
	Parikh K, Li C, Martin BC
	University of Arkansas for Medical Sciences, Little Rock, AR, USA
PRS37	CONCURRENT ASTHMA CONTROLLER MEDICATION POSSESSION PROFILES IN AN ADULT MANAGED CARE POPULATION
	Wagner S1, Langley P2
	1AstraZeneca, Wilmington, DE, USA, 2University of Minnesota, Minneapolis, MN, USA
PRS38	HEALTH CARE UTILIZATION CORRELATED WITH CONTROLLER DURATION DURING THE FIRST YEAR AFTER DIAGNOSIS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
	Blanchette CM1, St. Charles M2, Petersen H1, Silver H1
	1Lovelace Respiratory Research Institute, Albuquerque, NM, USA, 2IMS Health, Noblesville, IN, USA
PRS39	THE IMPACT OF FORMULARY POLICIES ON THE USE OF MEDICATION FOR RESPIRATORY DISEASE: A COMPARISON OF DRUG UTILIZATION IN THE PROVINCES OF ONTARIO AND ALBERTA
	Pilla J1, Dunn L1, Dranitsaris G2
	1Medication Use Management Inc, Toronto, ON, Canada, 2Augmentium Pharma Consulting, Toronto, ON, Canada
PRS40	ABSENCE OF CONTROLLER DRUG USE AMONG ASTHMATIC PATIENTS AT RISK OF ASTHMA ATTACK
	Vaidya V, Hong SH
	University of Tennessee, Memphis, TN, USA
PRS41	AVAILABILITY AND PRICE OF TWO INHALATION MEDICINES FOR TREATMENT OF ASTHMA IN DIFFERENT STATES OF INDIA
	Kotwani A
	Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India
PRS42	ASTHMA DISEASE BURDEN, EVIDENTIARY REQUIREMENTS, AND FORMULARY CONSIDERATIONS AMONG MANAGED CARE AND EMPLOYER DECISION MAKERS REGARDING INHALED CORTICOSTEROIDS (ICS)
	O'Day K1, Salamanca-Brosig E1, Regan TS1, Boswell K1, Nightengale B1, Seal B2
	1Xcenda, Palm Harbor, FL, USA, 2Sanofi-Aventis, Bridgewater, NJ, USA
PRS43	ECONOMIC BURDEN OF ASTHMA AMONG CHILDREN IN THE UNITED STATES
	Bharmal M1, Kamble S2
	1Quintiles, Falls Church, VA, USA, 2The University of North Carolina at Charlotte, Charlotte, NC, USA
PRS44	ANALYSIS OF THE COSTS RELATED TO SMOKING HABITS OF BENEFICIARIES OF A BRAZILIAN HEALTH PLAN, WITH THE PURPOSE TO DEFINE TREATMENT STRATEGIES TO REIMBURSE FIRST LINE MEDICATIONS
	Reis Neto JP, Tovar C, Stefani S
	CAPESESP/CAPESAUDE, Rio de Janeiro, RJ, Brazil
PRS45	THE DEVELOPMENT AND VALIDATION OF A CONTEMPORARY ASTHMA POLICY MODEL
	Campbell JD, Veenstra DL, Garrison LP, Sullivan SD
	University of Washington, Seattle, WA, USA
PRS46	HOW PROCESS INFLUENCES SCIENTIFIC EVIDENCE FOR HEALTH CARE POLICYMAKERS, THE CASE OF ECONOMICS AND MEDICAL DECISION-MAKING PROCESSES
	Huttin CCH
	ENDEPUSresearch,Inc and University Paul Cezanne, Cambridge, MA, USA
PRS47	ASTHMA PHARMACOTHERAPY AND AT RISK NON-AFRICAN AMERICAN MINORITY POPULATIONS: EVIDENCE OF SUB-OPTIMAL CARE FROM THE NATIONAL AMBULATORY MEDICAL SURVEY 1998-2004
	Navaratnam P1, Balkrishnan R2
	1The Ohio State University, Columbus, OH, USA, 2The Ohio State University College of Pharmacy, Columbus, OH, USA

SENSORY SYSTEMS DISORDERS Clinical Outcomes Studies
PSS1	CO-MORBIDITIES INCREASE IN THE YEAR FOLLOWING A DIAGNOSIS OF PSORIASIS
	Rahman M1, Khan S1, Changolkar A2, Naim A1, Yuan Z3, Tang B1
	1Centocor, Inc, Horsham, PA, USA, 2SOAL PharmaTech Solutions, LLC, Philadelphia, PA, USA, 3Johnson and Johnson, Titusville, NJ, USA
PSS2	EFFICACY OF BIOLOGICAL TREATMENT IN PATIENTS WITH PSORIASIS; META-ANALYSIS
	Brodszky V1, Pentek M2, Karpati K1, Boncz I3, Sebestyén A4, Gulacsi L1
	1Corvinus University of Budapest, Budapest, Hungary, 2Flor Ferenc County Hospital, Kistarcsa, Hungary, 3University of Pécs, Pécs, Hungary, 4National Health Insurance Fund Administration, Budapest, Hungary
PSS3	COMPARING THE EFFECTIVENESS OF CORTISPORIN VS. CIPRODEX FOR ACUTE OTITIS EXTERNA IN THE LOUISIANA MEDICAID POPULATION
	Jain G, Parmar J, Jenkins T, Baggarly S, Lawrence L
	The University of Louisiana at Monroe, Monroe, LA, USA
PSS4	THE RCT EVIDENCE OF COMPARATIVE EFFECTIVENESS AND SAFETY OF TOPICAL GLAUCOMA MEDICATION
	Lee CW1, Buckley F2, Costello S2, Stoddart SD2, Kelly S1
	1Pfizer, Tadworth, Surrey, UK, 2Heron Evidence Development Ltd, Letchworth Garden City, Hertfordshire, UK
SENSORY SYSTEMS DISORDERS Cost Studies
PSS5	MEDICAL COST OF GLAUCOMA IN SWEDEN
	Ström O1, Buchholz P2, Walt JG3, Mesterton J1, Bengtsson B4, Heijl A4
	1i3 Innovus, Stockholm, Uppland, Sweden, 2Allergan Europe, Ettlingen, Germany, 3Allergan Inc, Irvine, CA, USA, 4Malmo University Hospital, Malmo, Sweden
PSS6	COST-EFFECTIVENESS OF INTERMITTENT VS. CONTINUOUS ANTI-TNF ALPHA THERAPY IN PLAQUE PSORIASIS
	Lloyd AC1, Webber JM2, Lebmeier M3, Conway P4, Warburton J3
	1Fourth Hurdle Consulting, London, UK, 2Fourth Hurdle Consulting Ltd, London, UK, 3Wyeth Pharmaceuticals, Maidenhead, UK, 4Wyeth Europa, Berkshire, UK
PSS7	THE COST-EFFECTIVENESS OF RANIBIZUMAB COMPARED TO PDT-V AND BSC FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION IN CANADA
	Lozano-Ortega G1, Machuk RW1, Hass HE2, Barbeau M2, Mathen MK3
	1Oxford Outcomes, Vancouver, BC, Canada, 2Novartis Pharmaceuticals Canada Inc, Dorval, QC, Canada, 3Misericordia Health Centre, Winnipeg, MB, Canada
PSS8	ESTIMATING COST-EFFECTIVENESS OF TOPICAL OCULAR HYPOTENSIVES FOR MAINTAINING PERSISTENT THERAPY USING AREA UNDER THE SURVIVAL CURVE
	Reardon G1, Schwartz GF2, Kotak S3
	1Informagenics, LLC, Worthington, OH, USA, 2Glaucoma Consultants, Greater Baltimore Medical Center; Wilmer Eye Institute, Johns Hopkins University; University of Maryland, Baltimore, MD, USA, 3Pfizer Inc, New York, NY, USA
PSS9	A COST-EFFECTIVENESS ANALYSIS OF TNF-ALPHA INHIBITORS IN COMPARISON TO OTHER STRATEGIES IN THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS: A DECISION ANALYSIS MODEL
	Viswanathan S, McGhan WF
	University of the Sciences in Philadelphia, Philadelphia, PA, USA
PSS10	COST-EFFECTIVENESS OF ANTI VEGF THERAPIES FOR WET AGE-RELATED MACULAR DEGENERATION - AMD IN BRAZIL: THE PRIVATE PAYER PERSPECTIVE
	Bueno RLP1, Lion E2
	1FEI, São Paulo, Brazil, 2Novartis Biociências S/A, São Paulo, Brazil
PSS11	A COST-EFFECTIVENESS ANALYSIS OF BRIMONIDINE/TIMOLOL
	Higginbotham E1, Stern L2, Walt JG3
	1Morehouse School of Medicine, Atlanta, GA, USA, 2Analytica International, New York, NY, USA, 3Allergan Inc, Irvine, CA, USA
PSS12	COST-EFFECTIVENESS ANALYSIS OF BEVACIZUMAB AND RANIBIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (AMD): A CLINICAL AND ECONOMIC COMPARISON OF TWO VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITOR TREATMENTS
	Patel JJ, Stull MA, Bounthavong M, Christopher MLD, Foster E, Morreale AP, Plowman BK, Boggie DT
	Veterans Affairs San Diego Healthcare System (VASDHS), San Diego, CA, USA
PSS13	COST–EFFECTIVE ANALYSIS OF PEGAPTANIB (MACUGEN®) AS COMPARED WITH RANIBIZUMAB (LUCENTIS®) FOR TREATING IN AGE–RELATED MACULAR DEGENERATION (AMD)
	Lu LY, McGhan W
	University of the Sciences, Philadelphia, PA, USA
PSS14	COST-EFFECTIVENESS OF THE TREATMENT FOR MODERATE TO SEVERE PSORIASIS IN MEXICO: INFLIXIMAB, ETANERCEPT AND EFALIZUMAB
	Muciño E1, Rivas R2, Zapata L2
	1Instituto de Salud Publica, Cuernavaca, Morelos, Mexico, 2Guia Mark, México, DF, Mexico
PSS15	THE COST-EFFECTIVENESS OF RANIBIZUMAB (LUCENTIS®) IN TREATING PATIENTS WITH PREDOMINANTLY CLASSIC, MINIMALLY CLASSIC, AND OCCULT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (AMD)
	Turpcu A, Hay JW
	University of Southern California, Los Angeles, CA, USA
PSS16	A COST-EFFECTIVENESS ANALYSIS OF TWO TOPICAL OPHTHALMIC ANTIBIOTIC SOLUTIONS INDICATED FOR THE TREATMENT OF BACTERIAL CONJUNCTIVITIS
	Waycaster C
	Alcon Laboratories Inc, Fort Worth, TX, USA
PSS17	ECONOMIC EVALUATION OF MELOXICAM SOLUTION 0.030% RESPECT AN OPHTHALMIC SODIUM DICLOFENAC SOLUTION 0.1% ON THE EYES OF PATIENTS WHO UNDERWENT TO LASIK LASER EYE SURGERY AT THE IMMEDIATELY POST-OPERATIVE TIME
	Baiza L
	Sophia Pharmaceuticals, Guadalajara, Jalisco, Mexico
PSS18	COST-EFFECTIVENESS OF THE BIOLOGIC AGENTS UTILIZED IN THE TREATMENT OF CHRONIC PLAQUE PSORIASIS: A MARKOV MODEL
	Goldberg LD1, Feldman SR2, Marshall TS3, Jaracz E3
	1Goldberg, MD & Associates, Battle Ground, WA, USA, 2Wake Forest University School of Medicine, Winston Salem, NC, USA, 3Astellas Pharma US, Deerfield, IL, USA
PSS19	A PHARMACOECONOMIC EVALUATION OF PEGAPTANIB FOR THE MANAGEMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) IN MEXICO
	Vega-Hernández GY1, Idrovo-Velandia J2, Rivas R3, Zapata L3, Venegas J4, Ramírez H5, Mould-Quevedo J6, Davila-Loaiza G6
	1Pfizer Mexico, DF, Mexico City, Mexico, 2Insituto Nacional de Salud Pública, Cuernavaca, Morelos, Morelos, Mexico, 3Guia Mark, México, DF, Mexico, 4Guiamark SC, Mexico City, Mexico, 5Guiamark SC, Mexico City, Mexico City, Mexico, 6Pfizer Mexico, Mexico City, Mexico
PSS20	COST-EFFECTIVENESS OF TOBRADEX VERSUS ZYLET FOR THE TREATMENT OF BLEPHAROKERATOCONJUNCTIVITIS
	Rahman A1, Waycaster C2, Smith D1
	1Shenandoah University, Winchester, VA, USA, 2Alcon Laboratories Inc, Fort Worth, TX, USA
PSS21	COST OF ILLNESS OF WORK-RELATED CHRONIC HAND ECZEMA IN GERMANY
	Diepgen T1, Hieke K2
	1University Hospital Heidelberg, Heidelberg, Germany, 2NEOS Health (a COPERA company), Binningen, Switzerland
PSS22	THE ANNUAL COST OF BACTERIAL CONJUNCTIVITIS IN THE UNITED STATES: EVIDENCE FROM AN ECONOMIC MODELLING APPROACH
	Smith AF1, Waycaster C2
	1Medmetrics Inc, Ottawa, ON, Canada, 2Alcon Laboratories Inc, Fort Worth, TX, USA
PSS23	PROACTIVE USE OF TACROLIMUS 0.03% OINTMENT IN CHILDREN WITH MODERATE OR SEVERE ATOPIC DERMATITIS – OUTCOMES AND COST
	Thaçi D1, Sidhu M2, Dorsch B3, Köhne-Volland R3, Ehlken B4, Berger K4
	1University Hospital of J W Goethe University, Frankfurt, Germany, 2Astellas Pharma Europe Ltd, Staines, Middlesex, UK, 3Metronomia Clinical Research GmbH, München, Germany, 4IMS Health, Munich, Germany
PSS24	TRENDS IN EPISODE OF TREATMENT COSTS OF ACNE ACROSS THE UNITED STATES
	Balkrishnan R1, Uhas AA2, Feldman SR3
	1The Ohio State University, Columbus, OH, USA, 2The Ohio State University College of Pharmacy, Columbus, OH, USA, 3Wake Forest University School of Medicine, Winston Salem, NC, USA
PSS25	PHARMACOECONOMIC STUDY OF WET AGE-RELATED MACULAR DEGENERATION (AND)TREATMENT IN MEXICO
	Soria-Cedillo IF1, Robledo JL2, Carrazana E2, Garcia-Contreras F3
	1Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, Mexico, 2Novartis Farmacéutica S.A. de C.V, Mexico City, Mexico City, Mexico, 3Mexican Institute of Social Security, Mexico City, Mexico City, Mexico
PSS26	USING COST-UTILITY ANALYSIS TO ASSESS THE BUDGET IMPACT OF BIOLOGICS FOR THE TREATMENT OF PSORIASIS (PSO)
	Spiegel BM1, Patel V2, Chiou CF2, Esrailian E1
	1VA Greater Los Angeles Healthcare System; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, 2Amgen Inc, Thousand Oaks, CA, USA
SENSORY SYSTEMS DISORDERS Patient-Reported Outcomes
PSS27	USING MEDICATION POSSESSION AND DAYS OF COVERAGE ON THERAPY TO ASSESS PERSISTENCE WITH PROSTAGLANDIN OCULAR HYPOTENSIVE THERAPY
	Kotak S1, Schwartz GF2, Reardon G3, Shah SN1
	1Pfizer Inc, New York, NY, USA, 2Glaucoma Consultants, Greater Baltimore Medical Center; Wilmer Eye Institute, Johns Hopkins University; University of Maryland, Baltimore, MD, USA, 3Informagenics, LLC, Worthington, OH, USA
PSS28	DISTANCE VISUAL ACUITY AS A MEASURE OF VISION FUNCTION – INSIGHT INTO THE ASSOCIATION OF ETDRS LETTERS AND SELF-REPORT IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NV-AMD)
	Pleil A1, Buggage R2, Chen L2, Barsdorf A2, Zlateva G2
	1Pfizer Inc, San Diego, CA, USA, 2Pfizer Inc, New York, NY, USA
PSS29	USTEKINUMAB IMPROVES DISEASE SPECIFIC HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS: RESULTS WITH THE DERMATOLOGY LIFE QUALITY INDEX
	Lebwohl M1, Papp K2, Schenkel B3, Eisenberg D3, Yeilding N4, Guzzo C4, Wang Y4, Li S4, Krueger GG5
	1Mount Sinai School of Medicine, New York, NY, USA, 2Probity Medical Research, Waterloo, ON, Canada, 3J&J Pharmaceutical Services L.L.C, Horsham, PA, USA, 4Centocor Research and Development, Inc, Malvern, PA, USA, 5University of Utah Health Sciences Center, Salt Lake City, UT, USA
PSS30	USTEKINUMAB SIGNIFICANTLY IMPROVES QUALITY OF LIFE IN PATIENTS WITH PSORIASIS: RESULTS FROM A PHASE III STUDY
	Langley R1, Lebwohl M2, Krueger GG3, Yeilding N4, Guzzo C4, Wang Y4, Li S4, Schenkel B5, Reich K6, Leonardi C7
	1Dalhousie University, Halifax, NS, Canada, 2Mount Sinai School of Medicine, New York, NY, USA, 3University of Utah Health Sciences Center, Salt Lake City, UT, USA, 4Centocor Research and Development, Inc, Malvern, PA, USA, 5J&J Pharmaceutical Services L.L.C, Horsham, PA, USA, 6University Hospital, Gottingen, Germany, 7St. Louis University Medical Hospital, St. Louis, MO, USA
PSS31	ASSESSMENT OF QUALITY OF LIFE IN DAILY CLINICAL DERMATOLOGICAL ROUTINE: QUESTIONNAIRES AND CHECKLIST
	Tabolli S1, Abeni D2, Di Pietro C2, Sampogna F2
	1IDI IRCCS, ROME, Italy, 2IDI IRCCS, Rome, Italy
PSS32	QUALITY OF LIFE AND PSYCOLOGICAL DISTRESS IN PATIENT WITH CUTANEUOS LYMPHOMA
	Sampogna F1, Frontani M1, Baliva G1, Russo G1, Di Pietro C1, Abeni D1, Tabolli S2
	1IDI IRCCS, Rome, Italy, 2IDI IRCCS, ROME, Italy
PSS33	INTERNATIONAL DEVELOPMENT OF THE FIRST QUALITY OF LIFE INSTRUMENT SPECIFIC TO COSMETOLOGY AND PHYSICAL APPEARANCE: THE BEAUTYQOL INITIATIVE
	Beresniak A1, Auquier P2, Duru G3, Krueger GG4, Talarico S5, Tsutani K6, De Linares Y7, Berger G8
	1Data Mining International, Geneva, Switzerland, 2Laboratoire de Santé Publique, Marseilles, France, 3National Centre of Scientific Research, Lyon, France, 4School of medicine, S.L.C, UT, USA, 5Federal University of Sao Paulo, Sao Paulo, Brazil, 6Tokyo University, Tokyo, Japan, 7L'Oréal International, Asnieres sur Seine, France, 8University Pierre&Marie Curie, Paris, France
PSS34	QUALITY OF LIFE IN PATIENTS WITH VITILIGO. USE OF SINGLE ITEM ANALYSIS
	Sampogna F1, Tabolli S2, Raskovic D1, Guerra L1, Abeni D1
	1IDI IRCCS, Rome, Italy, 2IDI IRCCS, ROME, Italy
PSS35	THE IMPACT OF GLAUCOMA ON QUALITY OF LIFE: COMPARISON WITH THE CHRONIC DISEASES OSTEOPOROSIS, TYPE 2 DIABETES MELLITUS, AND DEMENTIA
	Walt JG1, Mills T2, Hansen JE1
	1Allergan Inc, Irvine, CA, USA, 2Wolters Kluwer Health, Chester, UK
PSS36	COMPARISON OF THE QUALITY OF LIFE IMPACT OF PERIPHERAL VISION LOSS VERSUS CENTRAL VISION LOSS
	Walt JG1, Evans K2, Hansen JE1
	1Allergan Inc, Irvine, CA, USA, 2Wolters Kluwer Health, Chester, UK
PSS37	MAPPING THE DERMATOLOGY QUALITY OF LIFE INDEX (DLQI) TO HEALTH-RELATED UTILITY VIA THE SF-12 IN SUBJECTS WITH ECZEMA
	Currie CJ1, Sidhu M2, Poole CD3
	1Cardiff University, Cardiff, UK, 2Astellas Pharma Europe Ltd, Staines, Middlesex, UK, 3Pharmatelligence, Cardiff, South Glamorgan, UK
PSS38	PATIENTS' PERCEPTION OF LIFE FREE OF GLASSES AFTER CATARACT SURGERY: DEVELOPMENT OF THE FREEDOM FROM GLASSES VALUE SCALE (FGVS©)
	Arnould B1, Benmedjahed K1, Berdeaux G2, Gil-Campos I3, Vigneux M4, Guillemin I1
	1Mapi Values France, Lyon, France, 2Alcon France, Rueil-Malmaison, France, 3Mapi Research Institute, Lyon, France, 4Mapi Values, Lyon, France
PSS39	ESTIMATING HEALTH RELATED UTILITY FROM SYMPTOM SEVERITY IN ATOPIC DERMATITIS (ECZEMA)
	Poole CD1, Sidhu M2, Currie CJ3
	1Pharmatelligence, Cardiff, South Glamorgan, UK, 2Astellas Pharma Europe Ltd, Staines, Middlesex, UK, 3Cardiff University, Cardiff, UK
PSS40	QUALITY OF LIFE AND PSYCHOLOGICAL PROBLEMS IN PATIENTS WITH ORAL MUCOSAL DISEASES
	Tabolli S1, Di Pietro C2, Sampogna F2, Abeni D2
	1IDI IRCCS, ROME, Italy, 2IDI IRCCS, Rome, Italy
PSS41	APPLES AND ORANGES? ASSESSING THE RELATIONSHIP BETWEEN HEALTH AND VISION RELATED QUALITY OF LIFE
	Kymes SM1, McIntosh LD1, Perron B2, Nease RF3, Sumner W4
	1Washington University, Saint Louis, MO, USA, 2University of Michigan, Ann Arbor, MI, USA, 3Express Scripts, Earth City, MO, USA, 4Washington University School of Medicine, Saint Louis, MO, USA
PSS42	MAPPING THE NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE (NEI-VFQ 25) TO THE INDEX VALUES FOR THE EQ-5D: A COMPARISON OF MODELS
	Payakachat N1, Pleil A2, Summers KH1
	1Purdue University, West Lafayette, IN, USA, 2Pfizer Inc, San Diego, CA, USA
PSS43	WORK RELATED LOST PRODUCTIVITY AND ITS ECONOMIC IMPACT IN CANADIAN PATIENTS WITH MODERATE TO SEVERE PSORIASIS
	Chan BCF1, Hales B1, Shear N2, Ho V3, Lynde C4, Poulin Y5, Mittmann N1
	1HOPE Research Centre, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3University of British Columbia, Vancouver, BC, Canada, 4Lynde Dermatology, Markham, ON, Canada, 5Laval University and Centre Dermatologique du Quebec metropolitain, Quebec City, QC, Canada
PSS44	USTEKINUMAB IMPROVES WORK PRODUCTIVITY AND DECREASES WORKDAYS MISSED DUE TO PSORIASIS IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS
	Reich K1, Lebwohl M2, Schenkel B3, Eisenberg D3, Szapary P4, Yeilding N4, Guzzo C4, Hsu MC4, Li S4, Gordon KB5
	1University Hospital, Gottingen, Germany, 2Mount Sinai School of Medicine, New York, NY, USA, 3J&J Pharmaceutical Services L.L.C, Horsham, PA, USA, 4Centocor Clinical Research and Development, Inc, Malvern, PA, USA, 5Evanston Northwestern Healthcare, Skokie, IL, USA
PSS45	VALUE OF DRIVING FOR PATIENTS WITH GLAUCOMA: WILLINGNESS TO PAY
	Walt JG1, Hansen JE1, Carlton R2, Bramley T3
	1Allergan Inc, Irvine, CA, USA, 2Xcenda, Palm Harbor, FL, USA, 3Xcenda, Salt Lake City, UT, USA
SENSORY SYSTEMS DISORDERS Health Care Use & Policy Studies
PSS46	PROSTAGLANDIN ANALOG USE WITH AND WITHOUT ADJUNCTIVE THERAPY FOR THE TREATMENT OF GLAUCOMA: A NETHERLANDS POPULATION BASED ANALYSIS
	Iskedjian M1, Walker JH2, Einarson TR3, Desjardins O4, Herings RMC5, Sukel M5, Covert D6
	1PharmIdeas, Buffalo, NY, USA, 2Brock University, Faculty of Business, St. Catharines, ON, Canada, 3University of Toronto, Toronto, ON, Canada, 4PharmIdeas Research and Consulting Inc, Oakville, ON, Canada, 5PHARMO Institute, Utrecht, Netherlands, 6Alcon Research Ltd, Forth Worth, TX, USA
PSS47	AN OBSERVATIONAL DATABASE ANALYSIS OF TREATMENT PATTERNS OF PATIENTS WITH PSORIASIS
	Mehra M, He J
	Johnson and Johnson Pharmaceutical Services, Raritan, NJ, USA
PSS48	HEALTH CARE COSTS INCREASE IN THE YEAR FOLLOWING A DIAGNOSIS OF PSORIASIS
	Rahman M1, Khan S1, Changolkar A2, Naim A1, Yuan Z3, Tang B1
	1Centocor, Inc, Horsham, PA, USA, 2SOAL PharmaTech Solutions, LLC, Philadelphia, PA, USA, 3Johnson and Johnson, Titusville, NJ, USA
PSS49	HEALTH CARE UTILIZATION INCREASES IN THE YEAR FOLLOWING A DIAGNOSIS OF PSORIASIS
	Rahman M1, Khan S1, Changolkar A2, Naim A1, Yuan Z3, Tang B1
	1Centocor, Inc, Horsham, PA, USA, 2SOAL PharmaTech Solutions, LLC, Philadelphia, PA, USA, 3Johnson and Johnson, Titusville, NJ, USA
PSS50	TRENDS IN MEDICATION PRESCRIBING FOR ACNE IN THE UNITED STATES ACCORDING TO PATIENT AGE
	Uhas AA1, Balkrishnan R2, Feldman SR3
	1The Ohio State University College of Pharmacy, Columbus, OH, USA, 2The Ohio State University, Columbus, OH, USA, 3Wake Forest University School of Medicine, Winston Salem, NC, USA

URINARY/KIDNEY DISORDERS Clinical Outcomes Studies
PUK1	CHRONIC KIDNEY DISEASE (CKD) AMONG INPATIENTS WITH REDUCED KIDNEY FUNCTION (RKF) ON HOSPITAL ADMISSION
	Yu HT1, Barlev A2, Emons MF1, Fiske KS3, Curkendall S4
	1Cerner LifeSciences, Beverly Hills, CA, USA, 2Amgen, Thousand Oaks, CA, USA, 3Cerner Corporation, Kansas City, MO, USA, 4Cerner LifeSciences, Vienna, WV, USA

PUK2	LONGITUDINAL DECLINE OF RENAL FUNCTION IN HYPERTENSIVE VETERANS
	Smith KL1, Ranger-Moore J2, Mohler MJ3, Armstrong EP1, Skrepnek GH1, Malone DC1
	1University of Arizona College of Pharmacy, Tucson, AZ, USA, 2University of Arizona Mel & Enid Zuckerman College of Public Health, Tucson, AZ, USA, 3University of Arizona College of Medicine, Tucson, AZ, USA

PUK3	EPIDEMIOLOGY AND OUTCOMES OF PATIENTS WITH CHANGES IN RENAL FUNCTION DURING HOSPITALIZATION THAT MAY REQUIRE DRUG DOSAGE ADJUSTMENT
	Gupta V, Derby KG, Tabak YP, Goetz A, Johannes RS, Darin R
	Cardinal Health, Marlborough, MA, USA
URINARY/KIDNEY DISORDERS Cost Studies
PUK4	COST-EFFECTIVENESS OF SEVELAMER IN THE TREATMENT OF HYPERPHOSPHATEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE IN MEXICO
	Idrovo J1, Rivas R2, Zapata L2
	1Guia Mark, Mexico, DF, Mexico, 2Guia Mark, México, DF, Mexico

PUK5	COST-EFFECTIVENESS OF CINECALCET IN THE TREATMENT OF SECONDARY HYPERPARATIROIDISM (SHPT)
	Pinto CG1, Weigert A2, Pissarra I3, Paquete AT4
	1Instituto Superior de Economia e Gestão, Technical University of Lisbon, Lisboa, Portugal, 2Santa Cruz Hospital, Carnaxide, Portugal, 3Instituto de Medicina Preventiva, Lisboa, Portugal, 4Research Centre on the Portuguese Economy - CISEP, Lisboa, Portugal

PUK6	FESOTERODINE FOR THE TREATMENT OF OVERACTIVE BLADDER – A COST-EFFECTIVENESS CASE STUDY OF SWEDEN
	Prütz C1, Snedecor S2, Botteman M2, Trocio J3, Weinstein D4
	1Pfizer AB, Stockholm, Sweden, 2Pharmerit North America, Bethesda, MD, USA, 3Pfizer Inc, New York, NY, USA, 4Pfizer France, Paris, France

PUK7	COST-EFFECTIVENESS OF IMMUNOSUPPRESSIVE REGIMENS IN RENAL TRANSPLANT RECIPIENTS IN GERMANY
	Hass B1, Arns W2, Kuchenbecker U3, Juergensen JS4
	1IMS HEALTH, Nuremberg, Germany, 2Kliniken der Stadt Koeln gGmbH, Cologne, Germany, 3Wyeth Pharma, Muenster, Germany, 4Charité-Universitaetsmedizin, Berlin, Germany

PUK8	A REVIEW: DIFFERING COSTS AND EFFECTS IN ECONOMIC EVALUATIONS OF TOLTERODINE FOR THE TREATMENT OF OVERACTIVE BLADDER
	Snedecor SJ1, Botteman MF1, Weinstein D2, Trocio J3
	1Pharmerit North America, LLC, Bethesda, MD, USA, 2Pfizer France, Paris, France, 3Pfizer Inc, New York, NY, USA

PUK9	HEALTH ECONOMIC EVALUATION OF PARICALCITOL COMPARED TO NON-SELECTIVE VITAMIN D RECEPTOR ACTIVATOR FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE PATIENTS: US PERSPECTIVE
	Nuijten MJ1, Marx SE2, Andress D2, Sterz R3
	1Ars Accessus Medica/Erasmus University Rotterdam, Amsterdam, Netherlands, 2Abbott, Abbott Park, IL, USA, 3Abbott GmbH & Co. KG, Ludwigshafen, Germany

PUK10	ECONOMIC EVALUATION OF POLYCLONAL ANTIBODIES FOR THE MANAGEMENT OF HIGH RISK PATIENTS WITH ACUTE REJECTION IN RENAL TRANSPLANTATION AT THE SOCIAL SECURITY MEXICAN INSTITUTE (IMSS)
	Salinas-Escudero G1, Contreras-Hernandez I2, Mould-Quevedo J3, Davila-Loaiza G3
	1Hospital Infantil de México Federico Gomez, Mexico City, Mexico, 2Social Security Mexican Institute, Mexico City, Mexico, 3Pfizer Mexico, Mexico City, Mexico

PUK11	URETEROSCOPY AND SHOCK WAVE LITHOTRIPSY FOR TREATMENT OF URETERAL STONES IN TAIWAN: ECONOMIC EVALUATION
	Lin CW
	I-Shou University, Kaohsiung, Taiwan

PUK12	COST-MINIMIZATION ANALYSIS OF EVEROLIMUS FOR KIDNEY TRANSPLANTATION IN BRAZIL
	Bueno RLP1, Prismich G2
	1FEI, São Paulo, Brazil, 2Novartis Biociências S/A, São Paulo, Brazil

PUK13	A COST MINIMIZATION ANALYSIS OF EPOETIN ZETA FOR THE TREATMENT OF ANEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE
	Pearson IV, Johnson KI
	Evidence Research Unit, Macclesfield, UK

PUK14	INPATIENT COSTS AND CLINICAL OUTCOMES OF S. AUREUS BLOODSTREAM AND NON-BLOODSTREAM INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE: FINDINGS FROM A MULTI-CENTER TRIAL
	Li Y1, Friedman JY1, O'Neal BF1, Hohenboken MJ2, Griffiths RI3, Stryjewski ME4, Schulman KA1, Inrig JK5, Fowler VG5, Reed SD1
	1Duke Clinical Research Institute, Durham, NC, USA, 2Nabi Biopharmaceuticals, Rockville, MD, USA, 3The Johns Hopkins University, Craftsbury, VT, USA, 4Centro De Educación Médica e Investigaciones Clínicas(CEMIC), Buenos Aires, Argentina, 5Duke University Medical Center, Durham, NC, USA

PUK15	COST IMPLICATIONS OF INTRAVENOUS (IV) BEVACIZUMAB TREATMENT IN PATIENTS WITH RENAL CELL CARCINOMA (RCC)
	Fournier AA1, Duh MS2, Moyneur É2, Dial E1, Neary MP3, Oh WK4
	1Analysis Group, Boston, MA, USA, 2Analysis Group, Inc, Boston, MA, USA, 3GlaxoSmithKline, Collegeville, PA, USA, 4Dana-Farber Cancer Institute, Boston, MA, USA

PUK16	COMPARATIVE ECONOMIC EVALUATION OF DUTASTERIDE VERSUS FINASTERIDE FOR MEDICARE-AGED MEN WITH BENIGN PROSTATIC HYPERPLASIA
	Lin PJ1, Shah M2, Davis EA3, Hogue SL4
	1GSK/University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2Xcenda, Palm Harbor, FL, USA, 3Independent Consultant, Research Triangle Park, NC, USA, 4GlaxoSmithKline, Research Triangle Park, NC, USA

PUK17	ECONOMIC EVALUATION OF SEVELAMER VERSUS CALCIUM-BASED PHOSPHATE BINDERS IN PATIENTS ON DIALYSIS IN THE UNITED KINGDOM SETTING
	Wex J, Timmaraju V, Schoppen S
	PharmArchitecture Limited, London, England, UK

PUK18	STAFF TIME AND COSTS FOR ANEMIA MANAGEMENT WITH ERYTHROPOIETIC STIMULATING AGENTS IN PATIENTS ON HEMODIALYSIS: CASE STUDY OF A BRAZILIAN DIALYSIS CENTER
	Canziani MEF1, Manfredi SR1, Saggia MG2, Nasciben V2
	1Federal University of São Paulo, São Paulo, SP, Brazil, 2Roche Brazil, Sao Paulo, SP, Brazil
URINARY/KIDNEY DISORDERS Patient-Reported Outcomes
PUK19	COMPARISON OF THE HEALTH-RELATED QUALITY OF LIFE BETWEEN PATIENTS UNDERGOING PERITONEAL DIALYSIS AND HAEMODIALYSIS
	Cortés-Sanabria L1, Cruz-Bueno Y2, Martinez-Martinez P3, Soto-Molina H4, Cueto-Manzano AM1
	1Hospital de Especialidades, CMNO, IMSS, Guadalajara, Jalisco, Mexico, 2Hospital de Ginecología y Obstetricia, CMNO, IMSS, Guadalajara, Jalisco, Mexico, 3HGR No. 110 "Oblatos", IMSS, Guadalajara, Jalisco, Mexico, 4Universidad Autonoma del Estado de México, Toluca, Mexico

PUK20	IMPROVEMENTS IN HEALTH-RELATED QUALITY OF LIFE WITH FESOTERODINE: KING'S HEALTH QUESTIONNAIRE ITEM ANALYSIS
	Khullar V1, Kelleher C2, Ellsworth P3, Martire D4, Wang J4, Trocio J4
	1St Mary's Hospital, London, UK, 2St. Thomas' Hospital, London, UK, 3Brown University, Cranston, RI, USA, 4Pfizer Inc, New York, NY, USA

PUK21	THE PSYCHOMETRIC VALIDATION OF AN US ENGLISH SATISFACTION MEASURE IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
	Black L1, Grove A2, Lin PJ3
	1GlaxoSmithKline, Research Triangle Park, NC, USA, 2Roundpeg Research, Abingdon, Oxfordshire, UK, 3GSK/University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

PUK22	ASSESSING PATIENT DESCRIPTIONS OF LOWER URINARY TRACT SYMPTOMS (LUTS) AND PERSPECTIVES ON TREATMENT OUTCOMES FOR THE DEVELOPMENT OF A NEW LUTS PATIENT REPORTED OUTCOME TOOL
	Coyne KS1, Sexton C1, Kopp Z2, Symonds T3, Aiyer L4, Kaplan S5, Chapple C6, Wein AJ7
	1United BioSource Corporation Center for Health Outcomes Research, Bethesda, MD, USA, 2Pfizer, Inc, New York, NY, USA, 3Pfizer Global Research & Development, Sandwich, Kent, UK, 4Pfizer Inc, New York, NY, USA, 5Weill Cornell Medical College, Cornell University, New York, NY, USA, 6The Royal Hallamshire Hospital, Sheffield, UK, 7University of Pennsylvania, Philadelphia, PA, USA

PUK23	EVALUATION OF FACE AND CONTENT VALIDITY OF NOCTURIA QUALITY OF LIFE QUESTIONNAIRE (N-QOL)
	Nixon A1, Wild D2, Goldfischer E3, Onel E4, Sendersky V5, Nielsen SK6
	1Oxford Outcomes Ltd, Oxford, Oxon, UK, 2Oxford Outcomes Ltd, Oxford, UK, 3Hudson Valley Urology, Poughkeepsie, NY, USA, 4Ferring Pharmaceuticals Inc, Parsippany, NJ, USA, 5Ferring Pharmaceuticals, Copenhagen, Denmark, 6Ferring International Center, Saint-Prex, Switzerland
URINARY/KIDNEY DISORDERS Health Care Use & Policy Studies
PUK24	POLYPHARMACY TREND IN WOMEN WITH CHRONIC KIDNEY DISEASE IN UNITED STATES OUTPATIENT SETTINGS
	Rasu R1, Abercrombie M2
	1University of Missouri- Kansas City, Kansas City, MO, USA, 2University of Missouri Kansas City, Kansas City, MO, USA

PUK25	DIALYSIS FACILITY CHARACTERISTICS INFLUENCE THE USE OF HOME DIALYSIS IN THE U.S.
	Walker DR, Inglese GW, Just PM
	Baxter Healthcare Corporation, McGaw Park, IL, USA

HEALTH CARE DECISION-MAKER’S CASE STUDIES
PCASE1	GCSF: SAVING COSTS WITHOUT SAVING QUALITY OF CARE. A UNIMED VITORIA HEALTH INSURANCE EXPERIENCE
	Figueira CM
	Unimed Vitória, Vitória, Espirito Santo, Brazil

PCASE2	THE ROLE OF ECONOMIC EVALUATION IN CHANGING DECISION-MAKER BEHAVIOURS : A CASE STUDY FROM TRINIDAD AND TOBAGO
	Bailey HH1, Kind P2, Dan DV3, La Foucade AD1
	1University of the West Indies, St. Augustine, Trinidad and Tobago; 2University of York, York, UK; 3San Fernando General Hospital, San Fernando, Trinidad and Tobago

PCASE3	PHARMACOECONOMIC APPLICATIONS IN FORMULARY MANAGEMENT: A CASE STUDY OF BORTEZOMIB AT A MAJOR CANCER CENTER
	Miller LA1, Raizada S2, Arbuckle R3, Lal L4
	1University of Texas - MD Anderson Cancer Center, Houston, TX, USA; 2University of Houston, Houston, TX, USA; 3MD Anderson Cancer Center, Houston, TX, USA; 4University of Texas MD Anderson Cancer Center, Houston, TX, USA

PCASE4	HEALTH PLAN AND INDUSTRY: NEW PARTNERSHIP TO ASSESS NEW TECHNOLOGY OUTCOMES AND ECONOMIC IMPACT
	Hume M1, De Oliveira J2, Fleury AV2, Nogueira E1
	1Johnson & Johnson Medical Brasil, São Paulo, SP, Brazil; 2Cassi, Brasília, DF, Brazil

PCASE5	INFORMING DECISION MAKERS IN GERMANY: THE IQWIG APPROACH
	Caro J1, Kolominsky-Rabas P2, McGregor M3, Henry D4
	1United BioSource Corporation, Concord, MA, USA; 2IQWiG, Koln, Germany; 3McGill University, Montreal, QC, Cambodia; 4Institute for Clinical and Evaluative Sciences, Toronto, ON, Canada

PCASE6	HOW SHOULD NEW TECHNOLOGIES AND NEW DEVICES BE ASSESSED IN A HOSPITAL SYSTEM?
	Mutnick AH1, Wong PK1, Matuszewski K2
	1Mercy Health Partners, Southwest Ohio, Cincinnati, OH, USA; 2University HealthSystem Consortium, Oak Brook, IL, USA

PCASE7	WITHDRAWN